<?xml version="1.0" encoding="UTF-8"?>
<!--Arbortext, Inc., 1988-2012, v.4002-->
<article xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table"
         xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:noNamespaceSchemaLocation="http://internal.acs.org/ACSJournal/JATS-archive-oasis-article1-mathml3.xsd"
         article-type="research-article"
         dtd-version="1.1d1">
   <front>
      <journal-meta>
         <journal-id journal-id-type="acspubs">cb</journal-id>
         <journal-id journal-id-type="coden">acbcct</journal-id>
         <journal-title-group>
            <journal-title>ACS Chemical Biology</journal-title>
            <abbrev-journal-title>ACS Chem.
Biol.</abbrev-journal-title>
         </journal-title-group>
         <issn pub-type="ppub">1554-8929</issn>
         <issn pub-type="epub">1554-8937</issn>
         <publisher>
            <publisher-name>American Chemical
Society</publisher-name>
         </publisher>
         <self-uri>pubs.acs.org/acschemicalbiology</self-uri>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.1021/cb500996u</article-id>
         <article-categories>
            <subj-group subj-group-type="document-type-name">
               <subject>Reviews</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>Small Molecule Inhibitors of Bromodomain–Acetyl-lysine
Interactions</article-title>
         </title-group>
         <contrib-group id="CONTRIB-GROUP-d386e26-autogenerated">
            <contrib contrib-type="author" id="ath1">
               <name name-style="western">
                  <surname>Brand</surname>
                  <given-names>Michael</given-names>
               </name>
               <xref rid="aff1"/>
            </contrib>
            <contrib contrib-type="author" id="ath2">
               <name name-style="western">
                  <surname>Measures</surname>
                  <given-names>Angelina
M.</given-names>
               </name>
               <xref rid="aff1"/>
            </contrib>
            <contrib contrib-type="author" id="ath3">
               <name name-style="western">
                  <surname>Wilson</surname>
                  <given-names>Brian G.</given-names>
               </name>
               <xref rid="aff1"/>
            </contrib>
            <contrib contrib-type="author" id="ath4">
               <name name-style="western">
                  <surname>Cortopassi</surname>
                  <given-names>Wilian A.</given-names>
               </name>
               <xref rid="aff1"/>
               <xref rid="aff2"/>
            </contrib>
            <contrib contrib-type="author" id="ath5">
               <name name-style="western">
                  <surname>Alexander</surname>
                  <given-names>Rikki</given-names>
               </name>
               <xref rid="aff3"/>
            </contrib>
            <contrib contrib-type="author" id="ath6">
               <name name-style="western">
                  <surname>Höss</surname>
                  <given-names>Matthias</given-names>
               </name>
               <xref rid="aff3"/>
            </contrib>
            <contrib contrib-type="author" id="ath7">
               <name name-style="western">
                  <surname>Hewings</surname>
                  <given-names>David
S.</given-names>
               </name>
               <xref rid="aff1"/>
            </contrib>
            <contrib contrib-type="author" id="ath10">
               <name name-style="western">
                  <surname>Rooney</surname>
                  <given-names>Timothy P. C.</given-names>
               </name>
               <xref rid="aff1"/>
            </contrib>
            <contrib contrib-type="author" id="ath8">
               <name name-style="western">
                  <surname>Paton</surname>
                  <given-names>Robert S.</given-names>
               </name>
               <xref rid="aff1"/>
               <xref rid="aff2"/>
            </contrib>
            <contrib contrib-type="author" corresp="yes" id="ath9">
               <name name-style="western">
                  <surname>Conway</surname>
                  <given-names>Stuart J.</given-names>
               </name>
               <xref rid="cor1"/>
               <xref rid="aff1"/>
            </contrib>
            <aff id="aff1"><label>†</label><institution id="d16e106" content-type="dept">Department
of Chemistry, Chemistry Research Laboratory</institution>, <institution>University of Oxford</institution>, <addr-line content-type="street-address">Mansfield Road</addr-line>, <addr-line content-type="city">Oxford</addr-line> <addr-line content-type="postal-code">OX1 3TA</addr-line>, <country>U.K.</country></aff>
            <aff id="aff2"><label>‡</label><institution id="d16e128" content-type="dept">Department
of Chemistry, Physical and Theoretical Chemistry Laboratory</institution>, <institution>University of Oxford</institution>, <addr-line content-type="street-address">South Parks Road</addr-line>, <addr-line content-type="city">Oxford</addr-line> <addr-line content-type="postal-code">OX1 3QZ</addr-line>, <country>U.K.</country></aff>
            <aff id="aff3"><label>§</label><institution>UCB</institution>, <addr-line content-type="street-address">208 Bath Road</addr-line>, <addr-line content-type="city">Slough</addr-line>, <addr-line content-type="state-csu">Berkshire</addr-line> <addr-line content-type="postal-code">SL1
3WE</addr-line>, <country>U.K.</country></aff>
         </contrib-group>
         <author-notes>
            <corresp id="cor1"><label>*</label>E-mail: <email>stuart.conway@chem.ox.ac.uk</email>.</corresp>
         </author-notes>
         <pub-date pub-type="epub">
            <day>30</day>
            <month>12</month>
            <year>2014</year>
         </pub-date>
         <pub-date pub-type="ppub">
            <day>16</day>
            <month>01</month>
            <year>2015</year>
         </pub-date>
         <volume>10</volume>
         <issue>1</issue>
         <issue-title>Post-Translational Modifications</issue-title>
         <fpage>22</fpage>
         <lpage>39</lpage>
         <history><date date-type="received"><day>05</day><month>12</month><year>2014</year></date><date date-type="accepted"><day>30</day><month>12</month><year>2014</year></date><date date-type="issue-pub"><day>16</day><month>01</month><year>2015</year></date><date date-type="just-accepted"><day>30</day><month>12</month><year>2014</year></date></history>
         <permissions>
            <copyright-statement>Copyright © 2014 American Chemical
Society</copyright-statement>
            <copyright-year>2014</copyright-year>
            <copyright-holder>American Chemical
Society</copyright-holder>
         </permissions>
         <abstract>
            <p content-type="toc-graphic"><graphic xlink:href="cb-2014-00996u_0009.tif" id="tgr1" orientation="portrait" position="float"/></p>
            <p content-type="abstract-graphic"><graphic xlink:href="cb-2014-00996u_0010.tif" id="abs1" orientation="portrait" position="float"/></p>
            <p>Bromodomains are protein modules
that bind to acetylated lysine
residues. Their interaction with histone proteins suggests that they
function as “readers” of histone lysine acetylation,
a component of the proposed “histone code”. Bromodomain-containing
proteins are often found as components of larger protein complexes
with roles in fundamental cellular process including transcription.
The publication of two potent ligands for the BET bromodomains in
2010 demonstrated that small molecules can inhibit the bromodomain–acetyl-lysine
protein–protein interaction. These molecules display strong
phenotypic effects in a number of cell lines and affect a range of
cancers <italic toggle="yes">in vivo</italic>. This work stimulated intense interest
in developing further ligands for the BET bromodomains and the design
of ligands for non-BET bromodomains. Here we review the recent progress
in the field with particular attention paid to ligand design, the
assays employed in early ligand discovery, and the use of computational
approaches to inform ligand design.</p>
         </abstract>
         <custom-meta-group>
            <custom-meta>
               <meta-name>document-id-old-9</meta-name>
               <meta-value>cb500996u</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>document-id-new-14</meta-name>
               <meta-value>cb-2014-00996u</meta-value>
            </custom-meta>
         </custom-meta-group>
      </article-meta>
   </front>
   <body>
      <sec id="sec1">
         <p>Lysine acetylation was identified
as a protein post-translational modification (PTM) by Allfey et al.,
in 1964, who observed both acetylation and methylation of histones
and suggested a role for these modifications in the regulation of
RNA synthesis.<xref rid="ref1" ref-type="bibr"/> Subsequently, the same
laboratory showed that acetylation was occurring on the ε-nitrogen
of lysine.<xref rid="ref2" ref-type="bibr"/> This PTM is, however, not limited
to histones, with one study identifying over 3600 sites of acetylation
on 1750 proteins derived from epithelial (A549) and lymphoid (Jurkat)
human cell lines.<xref rid="ref3" ref-type="bibr"/> The fundamental importance
of acetyl-lysine residues (KAc) and dynamic nature of this PTM was
further underlined by the identification of enzymes that alter the
lysine acetylation state, in the form of GCN5 as the first lysine/histone
acetyltransferase (KAT/HAT)<xref rid="ref4" ref-type="bibr"/> and HDAC1
the first histone deactylase.<xref rid="ref5" ref-type="bibr"/></p>
         <p>The
effect of lysine acetylation in histones was first recognized
as causing neutralization of the positive charge on lysine, resulting
in a weaker association with negatively charged DNA and a more relaxed
chromatin structure (euchromatin) that promotes transcriptional activation.
However, the identification of a protein module, the bromodomain,
which binds to KAc,<xref rid="ref6" ref-type="bibr"/> suggested a second
role for these residues, in which they mediate protein–protein
interactions (PPIs) involving histones through KAc–bromodomain
binding.<xref rid="ref7" ref-type="bibr"/> It has subsequently been shown
that this mechanism enables the assembly of protein complexes that
affect transcription. Non-histone proteins also bind to bromodomains;
for example, p53 is acetylated on lysine 382 and subsequently binds
to cAMP response element binding protein (CREB) binding protein (CREBBP)
via its bromodomain.<xref rid="ref8" ref-type="bibr"/></p>
         <p>Lysine acetylation
is now recognized as a protein PTM that is involved
in a multitude of fundamental cellular functions and might be viewed
as analogous to protein phosphorylation in terms of its prevalence
and importance.<named-content content-type="bibref-group"><xref rid="ref9" ref-type="bibr"/>,<xref rid="ref10" ref-type="bibr"/></named-content> This view is supported by the
emergence of the “histone code” hypothesis, which proposes
that PTMs, including lysine acetylation, on histones form a combinatorial
code that affects gene transcription. This hypothesis suggests that
a given pattern of marks on histone tails gives rise to specific downstream
functions, presenting new targets for therapeutic intervention.<named-content content-type="bibref-group"><xref rid="ref11" ref-type="bibr"/>,<xref rid="ref12" ref-type="bibr"/></named-content> This idea has resulted in the terms “writers” and
“erasers” being coined for enzymes that add or remove
a PTM, respectively. Similarly, protein modules, including bromodomains,
which bind PTMs, are termed “readers” of the histone
code.<xref rid="ref13" ref-type="bibr"/></p>
         <p>There are 61 bromodomains
that have been identified in 46 different
proteins in the human genome.<xref rid="ref14" ref-type="bibr"/> Recent
work, described below, has revealed that, despite mediating PPIs,<xref rid="ref15" ref-type="bibr"/> potent and drug-like small molecules that inhibit
the KAc–bromodomain interaction can be developed. These small
molecules have been instrumental in elucidating the biology of several
families of bromodomain-containing proteins (BCPs). This work has
resulted in five bromodomain ligands in clinical trials for a range
of indications. Here we describe the state of the art in the development
of bromodomain ligands and the application of these molecules to understand
the biology of BCPs.</p>
      </sec>
      <sec id="sec2">
         <title>Structure of Bromodomains</title>
         <fig id="fig1" position="float" orientation="portrait">
            <label>1</label>
            <caption>
               <p>(A) Histone tails are
subjected to multiple PTMs, including lysine
acetylation. Lysine acetylation state is “read” by bromodomains,
protein modules that invariably exist as part of a more complex protein
architecture. (B) The X-ray crystal structure of the BCP BRD4(1) bromodomain
in complex with the histone H4-mimicking peptide H4<sub>1–12</sub>KAc5KAc8 (carbon = purple, PDB code <ext-link ext-link-type="pdb" xlink:href="3UVW"/>). The KAc residue binds in a well-defined
pocket and, in BRD4(1), forms interactions with N140 and a second
interaction with Y97, via a structured water molecule. The peptide
binds across the WPF shelf, which is a hydrophobic region adjacent
to the KAc-binding pocket. The ZA channel is typically occupied by
two structural water molecules, at least in the BET bromodomains and
CREBBP. ET, extra terminal domain; CTM, C-terminal motif.</p>
            </caption>
            <graphic xlink:href="cb-2014-00996u_0001.tif"
                     id="gr1"
                     position="float"
                     orientation="portrait"/>
         </fig>
         <p>Bromodomains are compact protein modules comprising
approximately
110 amino acids that are found as part of larger protein architectures
(Figure <xref rid="fig1"/>A). Despite mediating PPIs, bromodomains
contain a defined and largely hydrophobic pocket that binds to acetylated
lysine residues on histones and also many other proteins (Figure <xref rid="fig1"/>B). The carbonyl oxygen atom of KAc binds to a highly
conserved asparagine residue at the top of helix B [N140 in BRD4(1)]
and forms a water-mediated hydrogen bond with a conserved tyrosine
residue [Y97 in BRD4(1)]. An interesting characteristic of those bromodomains
that have been investigated structurally is the four water molecules
that form the base of the KAc-binding pocket. In BRD4, the histone
peptide binds in a hydrophobic groove on the surface of the bromodomain.
Part of this groove is flanked by the residues W81, P82, and F83 and
is consequently termed the WPF shelf (Figure <xref rid="fig1"/>B). The ZA channel is a region of the bromodomain that is framed
by the ZA loop (Figure <xref rid="fig1"/>B). In the bromodomain
and extra terminal domain (BET) family of BCPs and the CREBBP bromodomain,
this channel contains two structural water molecules. However, the
size, nature, and water content of this channel vary significantly
between bromodomains.</p>
      </sec>
      <sec id="sec3">
         <title>Bromodomain and Extra Terminal Domain (BET)
Bromodomain-Containing
Proteins</title>
         <p>The BET family of BCPs, which comprises BRD2–4
and the testes
specific BRDT, has been the focus of most work in the area of bromodomain
ligand development.<named-content content-type="bibref-group"><xref rid="ref13" ref-type="bibr"/>,<xref rid="ref16" ref-type="bibr"/>−<xref rid="ref17" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref18" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref19" ref-type="bibr"/></named-content> The BET BCPs are all tandem bromodomain-containing
proteins with the first and second bromodomains located next to each
other toward the N-terminal of the proteins. There is greater similarity
between the first or second bromodomains of the BET family than between
the two bromodomains found in each BCP. BRD4 and BRDT have a central
role in the regulation of transcriptional elongation, which is mediated
by their interaction with the positive transcription elongation factor
B (P-TEFb), ultimately resulting in activation of RNA polymerase II.<named-content content-type="bibref-group"><xref rid="ref20" ref-type="bibr"/>,<xref rid="ref21" ref-type="bibr"/></named-content> While this association indicates that BRD4 has a general role in
transcription, inhibition of BRD4 bromodomain function affects only
a small subset of, usually lineage-specific, genes. Consequently,
BRD4 has been associated with a wide range of diseases and conditions.<xref rid="ref13" ref-type="bibr"/> The biology of BRD2 and BRD3 is less well understood
but is seemingly not redundant with respect to that of BRD4.</p>
      </sec>
      <sec id="sec4">
         <title>Discovery
and Development of BET Bromodomain Ligands</title>
         <fig id="fig2" position="float" orientation="portrait">
            <label>2</label>
            <caption>
               <p>Structures of key BET
bromodomain inhibitors (<bold>1</bold>–<bold>18</bold>) and
their IC<sub>50</sub> or <italic toggle="yes">K</italic><sub>D</sub> values with
the method used to obtain these values. The KAc-mimicking
component of the molecule, as determined by X-ray crystallography,
is shown in red. * indicates that BRD4(1) incorporates a L94A mutation.</p>
            </caption>
            <graphic xlink:href="cb-2014-00996u_0002.tif"
                     id="gr2"
                     position="float"
                     orientation="portrait"/>
         </fig>
         <p>Despite pioneering work by the
Zhou group on the development of
ligands for the PCAF<xref rid="ref22" ref-type="bibr"/> and CREBBP<xref rid="ref23" ref-type="bibr"/> bromodomains, it was the 2010 publication of
two diazepine-based potent pan-BET selective ligands, (+)-JQ1 (<bold>3</bold>)<xref rid="ref24" ref-type="bibr"/> and I-BET762 (<bold>1</bold>)<xref rid="ref25" ref-type="bibr"/> that ignited significant interest
in the bromodomains as therapeutic targets. It is notable that the
diazepine scaffold has a long history as the basis of drug molecules
and is viewed as a privileged structure that is particularly effective
at engaging with proteins.<named-content content-type="bibref-group"><xref rid="ref26" ref-type="bibr"/>,<xref rid="ref27" ref-type="bibr"/></named-content> It is perhaps significant
that the lead molecules for both ligands were discovered using a phenotypic
screening approach and that their cellular target was initially unknown.</p>
         <sec id="sec4.1">
            <title>Diazepine-Based
BET Bromodomain Ligands</title>
            <sec id="sec4.1.1">
               <title>I-BET762 (<bold>1</bold>)</title>
               <p>The discovery
of I-BET762
(<bold>1</bold>, Figure <xref rid="fig2"/>) was based on a phenotypic
screening approach to discover small molecule up-regulators of apolipoprotein
A1 (ApoA1), which is involved in protection from atherosclerosis progression
and with anti-inflammatory effects. When these studies commenced,
no molecular mechanism to achieve this up-regulation was known. A
luciferase reporter-based screen was used to identify small-molecule
enhancers of ApoA1 expression. Subsequent compound optimization led
to the development of I-BET762 (<bold>1</bold>), with an EC<sub>50</sub> value of 700 nM in the reporter gene assay. The benzodiazepine core
was essential for activity, as was the aryl group extending from the
6-position.<xref rid="ref28" ref-type="bibr"/> The C(4) stereochemistry
of the molecule had a significant influence on its potency, with only
the (<italic toggle="yes">S</italic>)-enantiomer showing activity, suggesting a
defined protein target for the molecule. A chemoproteomic approach
was used to identify the targets for the compound, which was found
to be the bromodomains of BRD2, BRD3, and BRD4. This proposed interaction
was confirmed by <italic toggle="yes">in vitro</italic> isothermal titration calorimetry
(ITC) and surface plasmon resonance (SPR) experiments. I-BET762 (<bold>1</bold>) bound to the tandem bromodomains of BRD2–4 [<italic toggle="yes">K</italic><sub>D</sub>(BRD4) = 55 nM by ITC] and displaced a tetra-acetylated
histone H4 peptide [IC<sub>50</sub>(BRD4) = 36 nM by fluorescence
resonance energy transfer (FRET)] while showing no affinity for bromodomains
outside the BET family.<named-content content-type="bibref-group"><xref rid="ref25" ref-type="bibr"/>,<xref rid="ref29" ref-type="bibr"/></named-content></p>
            </sec>
            <sec id="sec4.1.2">
               <title>Mitsubishi
Compounds and (+)-JQ1 (<bold>3</bold>)</title>
               <p>The
patent literature on compounds with the general core structure exhibited
by (+)-JQ1 (<bold>3</bold>, Figure <xref rid="fig2"/>) can be
traced back to at least 1996, when a patent<xref rid="ref30" ref-type="bibr"/> from Yoshitomi Pharma (later Welfide and then Mitsubishi Pharma)
details thienotriazolodiazepine-based compounds for use in the treatment
of autoimmune diseases including ulcerative colitis and Crohn’s
disease. A patent published by the same company in 2009 identified
the BET bromodomains as the targets for these compounds, leading to
suppression of cellular proliferation in tumor models.<xref rid="ref31" ref-type="bibr"/></p>
               <p>The triazolobenzodiazepine-based BET ligand,
(+)-JQ1 (<bold>3</bold>), was developed by Filippakopoulos et al.
based on compounds disclosed in the Mitsubishi patents.<named-content content-type="bibref-group"><xref rid="ref24" ref-type="bibr"/>,<xref rid="ref31" ref-type="bibr"/>,<xref rid="ref32" ref-type="bibr"/></named-content> Optimization of the benzodiazepine
core led to the highly potent compound (+)-JQ1, which was selective
for the BET BCPs over other families of BCPs and displayed an <italic toggle="yes">in vitro</italic> IC<sub>50</sub> of 77 nM (AlphaScreen).</p>
            </sec>
            <sec id="sec4.1.3">
               <title>Other
Diazepine-Based BET Bromodomain Ligands</title>
               <p>OTX015
(<bold>5</bold>, Figure <xref rid="fig2"/>) is a thienotriazolodiazepine-based
BET bromodomain inhibitor developed by OncoEthix. This compound is
very similar to (+)-JQ1, but has the <italic toggle="yes">tert-</italic>butyl ester
replaced by a (4-hydroxy)­phenyl-substituted carboxamide.<xref rid="ref33" ref-type="bibr"/> Researchers at Bayer have recently sought to
optimize the pharmacokinetic properties and solubility of I-BET762
by replacing the ethylamide group. Analysis of a number of substituents
in this position revealed a compound (<bold>8</bold>) with a 2-methyl-1,3,4-oxadiazole
replacement. This compound has an IC<sub>50</sub> value of 20 nM against
BRD4(1) by AlphaScreen.<xref rid="ref34" ref-type="bibr"/> MS417 (<bold>4</bold>, Figure <xref rid="fig2"/>) is another diazepine-based
BET bromodomain ligand, which was developed by the laboratory of Ming–Ming
Zhou. This compound contains a methyl ester in place of the <italic toggle="yes">tert</italic>-butyl ester of (+)-JQ1 (<bold>3</bold>) and binds to
BRD4(1) and BRD4(2) with similar affinities to (+)-JQ1.<xref rid="ref35" ref-type="bibr"/></p>
               <p>An interesting extension to the existing
diazepine-based BET bromodomain ligands, disclosed by Coferon, attempts
to capitalize on the tandem nature of the bromodomains in the BET
BCPs.<xref rid="ref36" ref-type="bibr"/> Two I-BET762 derivatives were synthesized,
which contain complementary diol and boronic acid moieties that link
covalently once both ligands are bound to one of the tandem bromodomains.
This linkage effectively forms a divalent ligand <italic toggle="yes">in situ</italic> and results in increased affinity for the target bromodomains on
the BET proteins. The drug would be administered in the form of covalently
linked dimers designed for optimal binding to the target protein.
The drug dissociates to monomers under physiological conditions, undergoing
reassembly upon target engagement.</p>
            </sec>
         </sec>
         <sec id="sec4.2">
            <title>3,5-Dimethylisoxazole-Based
Bromodomain Ligands</title>
            <p>The
3,5-dimethylisoxazole moiety has been independently discovered by
a number of groups as an excellent KAc mimic. Ligands based on this
KAc mimic have been developed for both the BET<named-content content-type="bibref-group"><xref rid="ref37" ref-type="bibr"/>−<xref rid="ref38" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref39" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref40" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref41" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref42" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref43" ref-type="bibr"/></named-content> and CREBBP<named-content content-type="bibref-group"><xref rid="ref37" ref-type="bibr"/>,<xref rid="ref44" ref-type="bibr"/>,<xref rid="ref45" ref-type="bibr"/></named-content> bromodomains, with evidence emerging to suggest this group will
also be an effective KAc mimic in other phylogenetically diverse bromodomains.</p>
            <p>Using a fragment-based approach, Hewings et al. identified 3,5-dimethylisoxazole-based
compounds as ligands for the BET BCPs with low micromolar affinity.<xref rid="ref37" ref-type="bibr"/> These compounds were of low molecular weight
and had good ligand efficiency and hence were suitable for further
development to give more potent ligands. By optimizing the interaction
of these compounds with the ZA channel and the WPF shelf of the BET
bromodomains, a more potent set of ligands was developed (<bold>9</bold>–<bold>10</bold>, Figure <xref rid="fig2"/>) that caused
reduced viability of lung adenocarcinoma cell lines.<xref rid="ref42" ref-type="bibr"/></p>
            <p>Scientists at GSK independently developed the 3,5-dimethyl­isoxazole
motif as a KAc mimic. The 3,5-dimethylisoxazole-containing BET-bromodomain
inhibitor, I-BET151 (<bold>11</bold>), was identified by phenotypic
screening and developed in parallel to I-BET762 (<bold>1</bold>).<xref rid="ref38" ref-type="bibr"/> This highly potent compound [BRD4 <italic toggle="yes">K</italic><sub>D</sub> = 100 nM by SPR, and <italic toggle="yes">K</italic><sub>D</sub> =
36 nM by fluorescence anisotropy (FA)] selectively binds to bromodomains
of the BET subfamily and has improved pharmacokinetic properties compared
to triazolobenzodiazepine scaffolds.<xref rid="ref40" ref-type="bibr"/></p>
            <p>Researchers at GSK also took a structure-based design approach
to developing 3,5-dimethylisoxazole-based BET bromodomain inhibitors.
Starting from 4-phenyl-3,5-dimethyl­isoxazole, it was shown that
a sulfonamide-linked lipophilic ring was effective at occupying the
WPF shelf, improving bromodomain affinity. The addition of a cyclopentyl
group gave a compound (<bold>12</bold>) with reasonable affinity for
the BET bromodomains.<xref rid="ref39" ref-type="bibr"/></p>
            <p>Researchers
at Constellation Pharmaceuticals reported an isoxazole-based
BET bromodomain ligand that was developed using hits from a fragment
screen.<xref rid="ref43" ref-type="bibr"/> This screen identified a number
of compounds with potencies in the micromolar range including the
5-amino-3-methyl-4-phenylisoxazole fragment. Analysis of cocrystal
structures of this fragment with BRD4(1) ultimately led to the development
of the carboxamide (<bold>6</bold>), which has an IC<sub>50</sub> value
of 26 nM against BRD4(1), similar to the values displayed by (+)-JQ1
(<bold>3</bold>) and I-BET151 (<bold>11</bold>) in the same assay.
In compound <bold>6</bold>, the isoxazole resides in the KAc-binding
pocket and acts as a KAc mimic, and the 4-chlorophenyl group binds
to the WPF shelf. The carboxamide NH<sub>2</sub> group forms a water-mediated
hydrogen bond with the carbonyl oxygen atom of N140 (Figure <xref rid="fig4"/>). Compound <bold>6</bold> was shown to be a potent
BET bromodomain probe in cellular assays, and pharmacokinetic profiling
in rat and dog demonstrated suitable characteristics for further <italic toggle="yes">in vivo</italic> experiments.</p>
            <p>Sharp et al. appended a range
of KAc-mimicking head groups to the
cyclopentylphenylsulfonamide scaffold to compare their ability to
bind to BRD2–4, using an AlphaScreen assay.<xref rid="ref46" ref-type="bibr"/> The previously identified 3,5-dimethylisoxazole and the
structurally related pyrazole showed the greatest affinity for the
BET bromodomains. The microsomal stability of the compounds was investigated
with the 3,5-dimethylisoxazole-based compound showing rapid metabolism.
However, the 3,5-dimethylisoxazole-based I-BET151 showed a much longer
half-life in the same assay, indicating the rapid metabolism is not
an inherent property of the 3,5-dimethylisoxazole motif.</p>
            <sec id="sec4.2.1">
               <title>RVX-208 (<bold>7</bold>)</title>
               <p>Like I-BET762 and I-BET151,
RXV-208 (<bold>7</bold>) was originally identified as an upregulator
of ApoA1 and progressed to Phase II clinical trials; subsequently
two studies showed that it binds to the BET bromodomains.<named-content content-type="bibref-group"><xref rid="ref47" ref-type="bibr"/>,<xref rid="ref48" ref-type="bibr"/></named-content> This compound is currently undergoing clinical development as a
treatment for atherosclerosis.<named-content content-type="bibref-group"><xref rid="ref49" ref-type="bibr"/>,<xref rid="ref50" ref-type="bibr"/></named-content> Unlike previously described
BET inhibitors, RVX-208 (<bold>7</bold>) shows modest selectivity
for the second over the first bromodomain of the BETs. For example,
ITC experiments carried out by Picaud et al. gave a <italic toggle="yes">K</italic><sub>D</sub> of 140 nM for BRD4(2), but 1.1 μM for BRD4(1).<xref rid="ref47" ref-type="bibr"/> It is currently unclear whether this selectivity
significantly affects the physiological action of the compound.</p>
            </sec>
            <sec id="sec4.2.2">
               <title>PFI-1 (<bold>14</bold>)</title>
               <p>The dihydroquinazolinone fragment
was independently identified as a ligand efficient KAc mimic by a
number of groups.<named-content content-type="bibref-group"><xref rid="ref37" ref-type="bibr"/>,<xref rid="ref51" ref-type="bibr"/>,<xref rid="ref52" ref-type="bibr"/></named-content> Fish et al.<xref rid="ref53" ref-type="bibr"/> employed this fragment
to develop the potent and selective BET-bromodomain probe, PFI-1 (<bold>14</bold>). Structure-based fragment assessment and optimization
techniques were used to develop a potent (BRD4(1) IC<sub>50</sub> =
220 nM; AlphaScreen) and ligand efficient compound with good selectivity
over a broad panel of phylogenetically diverse bromodomains determined
by differential scanning fluorimetry (DSF) analysis. Furthermore, <bold>14</bold> showed antiproliferative effects on several leukemia cell
lines in clonogenic growth assays. Studies in rats showed promising
pharmacokinetic results despite modest oral bioavailability. Data
reported in a separate publication showed that incubation of sensitive
cell lines with PFI-1 resulted in cell-cycle arrest and induction
of apoptosis.<xref rid="ref54" ref-type="bibr"/> Down-regulation of the
well-known oncology target Aurora B kinase <italic toggle="yes">in vitro</italic> was also achieved with this compound, potentially providing a valuable
alternative strategy to inhibit this important cancer target.</p>
            </sec>
            <sec id="sec4.2.3">
               <title>Thiazol-2-one-Based
Bromodomain Ligands</title>
               <p>Zhao et al.
at the State Key Laboratory of Drug Research in the Chinese Academy
of Sciences used a fragment-based approach to identify novel chemotypes
that form the basis of BET bromodomain inhibitors.<xref rid="ref55" ref-type="bibr"/> Forty-one putative BRD4-binding fragments were identified
using docking studies, and these hits were progressed to crystallographic
studies. Structure-based optimization of a 4-phenyl-thiazol-2-one-based
hit identified a number of compounds with submicromolar IC<sub>50</sub> values. Compound <bold>15</bold> had an IC<sub>50</sub> value of
230 nM in an FA assay for the displacement of fluorescein-tagged (+)-JQ1
from BRD4(1). The selectivity of this compound over other bromodomains
was not discussed. Activity in cellular assays, including growth inhibition
and <italic toggle="yes">MYC</italic> mRNA downregulation in HT-29 colon cancer
cells, showed little correlation with inhibitory activity in the FA
assay, perhaps as a result of limited membrane permeability. The most
potent of the compounds in the cellular assay was only moderately
active [GI<sub>50</sub> of 37 μM in HT-29 proliferation assay,
cf. 2.3 μM for (+)-JQ1].<xref rid="ref55" ref-type="bibr"/></p>
            </sec>
            <sec id="sec4.2.4">
               <title>Diazobenzene-Based
Bromodomain Ligands</title>
               <p>The laboratory
of Zhou and co-workers identified a diazobenzene-based compound <bold>27</bold>, ischemin, as a ligand for the CREBBP bromodomain (Figure <xref rid="fig5"/>).<xref rid="ref56" ref-type="bibr"/> The same group has
more recently employed a related scaffold to develop potent BET bromodomain
inhibitors.<xref rid="ref57" ref-type="bibr"/> MS436 (<bold>17</bold>) inhibited
the binding of fluorescein-tagged MS417 (<bold>4</bold>) to BRD4(1)
in an FA assay with a <italic toggle="yes">K</italic><sub>i</sub> value of &lt;85
nM (limited by the affinity of the assay probe). The compound also
showed activity against the bromodomains of CREBBP, PCAF, BRD7, BPTF,
BAZ2B, and SMARCA4, with <italic toggle="yes">K</italic><sub>i</sub> values between
2 and 8 μM in FA assays. The compound showed activity in a number
of cellular assays, including suppressing the release of the pro-inflammatory
cytokine IL-6 after LPS stimulation, with an IC<sub>50</sub> value
of 4.9 μM in an enzyme-linked immunosorbent assay (ELISA). Data
published in a patent from the same group demonstrated that the diazo
linker can be replaced with an alkene without loss of affinity.<xref rid="ref58" ref-type="bibr"/></p>
            </sec>
            <sec id="sec4.2.5">
               <title>4-Acylpyrroles, XD14 (<bold>18</bold>)</title>
               <p>Lucas et al.
used a virtual screening approach, followed by X-ray crystallography
and ITC measurements, to identify new inhibitors of BRD4(1).<xref rid="ref59" ref-type="bibr"/> The most active hit was <bold>18</bold>, XD14,
which has a <italic toggle="yes">K</italic><sub>D</sub> of 237 nM against BRD4(1)
by ITC and a <italic toggle="yes">K</italic><sub>D</sub> value of 160 nM in the
BROMO<italic toggle="yes">scan</italic> ligand displacement assay. Compound <bold>18</bold> also interacts significantly with the CREBBP bromodomain
displaying a <italic toggle="yes">K</italic><sub>D</sub> value of 1.6 μM
(BROMO<italic toggle="yes">scan</italic>), but it showed good selectivity over
other bromodomains from outside the BET family. The compound was crystallized
with BRD4(1), and the X-ray structure revealed that the ketone carbonyl
group mimics the carbonyl of KAc in its hydrogen-bonding interactions,
while a methyl group at C(5) occupies a similar position as the terminal
methyl group of KAc (Figure <xref rid="fig4"/>).</p>
            </sec>
            <sec id="sec4.2.6">
               <title>I-BET726
(GSK1324726A, <bold>16</bold>)</title>
               <p>Compound <bold>16</bold>,
I-BET726, is based on the 1-acetyl tetrahydroquinoline
KAc mimic, which was originally disclosed in a GSK patent filed in
2010<xref rid="ref60" ref-type="bibr"/> and was recently published by Wyce
et al.<xref rid="ref61" ref-type="bibr"/> and Gosmini et al.<xref rid="ref62" ref-type="bibr"/> I-BET726 binds to the tandem bromodomains of
BRD4 with a <italic toggle="yes">K</italic><sub>D</sub> of 4 nM by ITC (IC<sub>50</sub> value of 22 nM in a TR-FRET assay). It shows excellent selectivity
against the closely related CREBBP bromodomain with a <italic toggle="yes">K</italic><sub>D</sub> value of 6.3 μM (ITC) and no significant activity
against a panel of other bromodomains. I-BET726 has been extensively
profiled in cells, and shows potent antiproliferative activity in
many, but not all, solid tumor cell lines tested, with IC<sub>50</sub> values in a 6-day growth inhibition assay of less than 50 nM in
some neuroblastoma cell lines.</p>
            </sec>
         </sec>
         <sec id="sec4.3">
            <title>Dual Kinase–Bromodomain
Inhibitors</title>
            <fig id="fig3" position="float" orientation="portrait">
               <label>3</label>
               <caption>
                  <p>Dual kinase–bromodomain inhibitors. The structures
of reported
dual kinase–bromodomain inhibitors (<bold>19</bold>–<bold>23</bold>) and their IC<sub>50</sub> or <italic toggle="yes">K</italic><sub>D</sub> values with the method used to obtain these values. The KAc-mimicking
component of the molecule, as determined by X-ray crystallography,
is shown in red. Note that <bold>19</bold> shows different binding
modes when crystallized with BRD4(1) and BRDT, perhaps reflecting
its low affinity for these bromodomains. The classic hinge-binding
motif interacts with N140 in BRD4(1) (PDB ID: <ext-link ext-link-type="pdb" xlink:href="4O70"/>) whereas the pyridine <italic toggle="yes">N</italic>-oxide interacts with N109 in BRDT (PDB ID: <ext-link ext-link-type="pdb" xlink:href="4KCX"/>).</p>
               </caption>
               <graphic xlink:href="cb-2014-00996u_0003.tif"
                        id="gr3"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>A number of kinase inhibitors have been identified
as binding to
the KAc-binding pocket of some bromodomains, often with affinities
that have implications for their <italic toggle="yes">in vivo</italic> activity.
Martin et al. showed that Dinaciclib (<bold>19</bold>, Figure <xref rid="fig3"/>), a cyclin-dependent kinase (CDK) inhibitor currently
in Phase III trials for chronic lymphocytic leukemia, was observed
crystallographically to occupy the KAc binding pocket of BRDT(1).<xref rid="ref63" ref-type="bibr"/> However, analysis in the BROMO<italic toggle="yes">scan</italic> assay revealed only weak binding, with a <italic toggle="yes">K</italic><sub>D</sub> value of 37 μM.</p>
            <p>LY294002 (<bold>20</bold>), a
phosphoinositide 3-kinase (PI3K) inhibitor and widely used chemical
probe, also interacts with BET bromodomains. Titrating LY294002 to
compete bromodomains away from an immobilized LY294002 derivative
gave an apparent <italic toggle="yes">K</italic><sub>D</sub> value of 2 μM
for BRD4. LY294002 also showed cellular effects consistent with BET
bromodomain inhibition, including suppression of cytokine release
after LPS stimulation.<xref rid="ref64" ref-type="bibr"/> Neither study
investigated whether these compounds could inhibit the reported kinase
activity of BRD4.<xref rid="ref65" ref-type="bibr"/> Interestingly, BRD4
was identified as a cellular target of LY294002 in 2007 by a similar
chemoproteomic approach using an immobilized inhibitor.<xref rid="ref66" ref-type="bibr"/> Furthermore, a study in 2005 showed that LY294002
inhibited NF-κB-dependent transcription and nitric oxide production,
while another PI3K inhibitor, wortmannin, did not.<xref rid="ref67" ref-type="bibr"/> It seems likely that these effects result from BRD4 inhibition.<named-content content-type="bibref-group"><xref rid="ref68" ref-type="bibr"/>,<xref rid="ref69" ref-type="bibr"/></named-content></p>
            <p>Ciceri et al. screened 628 kinase inhibitors against BRD4(1)
(AlphaScreen)
to identify kinase inhibitors that displayed potent BET bromodomain
affinity, with the aim of developing single agent dual kinase–bromodomain
inhibitors for cancer therapy.<xref rid="ref70" ref-type="bibr"/> The screened
compound collection contained more than 200 clinical kinase inhibitors.
A number of these compounds were found to be potent BRD4(1) ligands,
with the PLK1 inhibitor BI2536 (<bold>21</bold>) having <italic toggle="yes">K</italic><sub>D</sub> value of 37 nM for BRD4(1) and the JAK inhibitors TG101348
(<bold>22</bold>) and TG101209 (<bold>23</bold>) having <italic toggle="yes">K</italic><sub>D</sub> values of 164 and 123 nM for BRD4(1), respectively.
BI2536 (<bold>21</bold>) and TG101348 (<bold>22</bold>) were shown
to disrupt the binding of BRD4 to chromatin in a fluorescence recovery
after photobleaching (FRAP) assay in U2OS cells. It is suggested that
the BET bromodomains, and not the JAK kinases, are the key targets
for these compounds, at least in certain cell lines. On the basis
of the analysis in this paper, the authors propose a method for the
rational design of dual kinase–bromodomain inhibitors that
possess complementary pharmacology for use in cancer therapy. In related
work, Ember et al. identified 14 kinase inhibitors as BRD4(1) ligands
that occupy the KAc-binding site.<xref rid="ref71" ref-type="bibr"/> This
study also identified BI2536 (<bold>21</bold>) and TG101209 (<bold>23</bold>) as among the most potent BRD4(1) ligands reported to date.</p>
         </sec>
      </sec>
      <sec id="sec5">
         <title>Selectivity between the First and Second Bromodomains of BET
BCPs</title>
         <p>Since there are no known links between pathology and
the function
of individual bromodomains, it is unknown whether gaining selectivity
over each of the tandem BET bromodomains could be beneficial in treating
disease or mitigating unwanted effects. In an attempt to identify
the different functions of the first and second bromodomains of the
BET BCPs, Baud et al.<xref rid="ref72" ref-type="bibr"/> took a “bump
and hole approach”.<xref rid="ref73" ref-type="bibr"/> A L94A mutation
 of BRD4(1) allowed an I-BET762-based ligand to be developed (<bold>2</bold>, Figure <xref rid="fig2"/>) that shows 540-fold selectivity
for the mutated protein over the WT protein (ITC).<xref rid="ref72" ref-type="bibr"/> The selectivity was exploited using a FRAP assay in U2OS
cells transfected with full-length human, single and double mutation <italic toggle="yes">Brd4</italic>, to demonstrate that targeting the first bromodomain
was sufficient to disrupt the interaction of BRD4 with chromatin.</p>
         <p>RVX-208 (<bold>7</bold>, Figure <xref rid="fig2"/>) shows
a 40-fold selectivity of BET(2) over BET(1) in BRD4, although this
selectivity is not by design. It is unclear what the impact the different
affinities for each bromodomain has on the biological function of
the compound.<named-content content-type="bibref-group"><xref rid="ref47" ref-type="bibr"/>,<xref rid="ref48" ref-type="bibr"/></named-content> Additionally, researchers at
GSK reported the novel thienopyridinone, furopyridine and tetrahydroquinoline
scaffolds with up to 10-fold selectivity for BRD4(1) over BRD4(2)
in BRD4.<named-content content-type="bibref-group"><xref rid="ref74" ref-type="bibr"/>−<xref rid="ref75" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref76" ref-type="bibr"/></named-content> At the same time scientists at Abbvie showed a similar
scaffold, pyrrolopyridinone, is able to invert the interdomain selectivity
by changing the substituents.<xref rid="ref77" ref-type="bibr"/></p>
      </sec>
      <sec id="sec6">
         <title>Comparison
of Acetyl-lysine Mimicking Groups</title>
         <p>Significant progress has
been made in developing BET bromodomain
ligands based on a diverse range of chemotypes, which allows a comparison
of the range of KAc mimics that have been employed. Figure <xref rid="fig4"/> shows the binding of <bold>1</bold>, <bold>3</bold>, <bold>6</bold>, <bold>7</bold>, <bold>9</bold>, and <bold>14</bold>–<bold>18</bold> to BRD4(1). All of the
KAc-mimicking groups form a water-mediated hydrogen bond to Y97, a
residue that is largely conserved in human bromodomains. Additionally,
all KAc mimics receive a hydrogen bond from the NH<sub>2</sub> of
the Asn residue at the top of helix B [N140 in BRD4(1)]. In some mimics
both interactions are made by the same atom, and in others the interactions
are made by two different atoms. Two compounds (<bold>7</bold>, <bold>14</bold>) donate a third hydrogen bond to the carbonyl oxygen atom
of N140. It seems that the two hydrogen bonds that are observed in
all potent BET inhibitors are important for binding to the bromodomain,
although it is unclear whether this is primarily an orientation effect
or these hydrogen bonds contribute enthalpically to the affinity of
the ligands. As the two ligands that form a third hydrogen bond do
not show substantially higher affinity, compared to ligands with two
hydrogen bonds, it seems reasonable to assume that the formation of
this third hydrogen bond does not contribute significantly to the
binding energy of the ligands. Within the KAc-binding pocket there
is a hydrophobic wall formed on one side by V87, L92, L94, Y97, and
Y139 (BRD4(1) numbering). On the opposite side, W81 and I146 present
a hydrophobic surface to the KAc binding pocket. It seems that many
BET bromodomain ligands derive their affinity from effective hydrophobic
interactions with these residues and also with the hydrophobic WPF
shelf.</p>
         <p>The compounds described above are proving to be valuable
tools
in understanding the function of the BET bromodomains.</p>
         <fig id="fig4" position="float" orientation="portrait">
            <label>4</label>
            <caption>
               <p>Comparison of the KAc
mimicking groups in compounds <bold>1</bold>, <bold>3</bold>, <bold>6</bold>, <bold>7</bold>, <bold>9</bold>,
and <bold>14</bold>–<bold>18</bold> binding to the KAc binding
pocket of BRD4(1). Many of the residues that form the KAc-binding
pocket have been omitted for clarity. This pocket is much more enclosed
than implied by the representations above.</p>
            </caption>
            <graphic xlink:href="cb-2014-00996u_0004.tif"
                     id="gr4"
                     position="float"
                     orientation="portrait"/>
         </fig>
      </sec>
      <sec id="sec7">
         <title>Ligands for Non-BET Bromodomains</title>
         <sec id="sec7.1">
            <title>CREBBP Bromodomain Ligands</title>
            <fig id="fig5" position="float" orientation="portrait">
               <label>5</label>
               <caption>
                  <p>Structures
of key CREBBP bromodomain inhibitors (<bold>24</bold>–<bold>31</bold>) and their IC<sub>50</sub> or <italic toggle="yes">K</italic><sub>D</sub> values with the method used to obtain these values.
The KAc-mimicking component of the molecule, as determined by X-ray
crystallography, is shown in red, where known.</p>
               </caption>
               <graphic xlink:href="cb-2014-00996u_0005.tif"
                        id="gr5"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>CREBBP, also known as CBP, is another BCP that has emerged
as a
target for small molecule bromodomain inhibitors. CREBBP was discovered
as a nuclear protein that binds to phosphorylated CREB; it regulates
protein kinase A activity as part of a multiprotein complex.<xref rid="ref78" ref-type="bibr"/> CREBBP’s paralogue, p300 (EP300), was
discovered as a binding partner of the adenovirus early region 1A
protein (E1A).<xref rid="ref79" ref-type="bibr"/> Both CREBBP and p300 were
later shown to possess HAT activity.<named-content content-type="bibref-group"><xref rid="ref80" ref-type="bibr"/>,<xref rid="ref81" ref-type="bibr"/></named-content> The two proteins
have at least 400 interacting protein partners making them key nodes
in the known mammalian protein–protein interactome.<xref rid="ref82" ref-type="bibr"/> One such partner is p53, and the specific recognition
of KAc382 of p53 by the CREBBP/p300 bromodomain is required for acetylation-dependent
coactivator recruitment after DNA damage. The multidomain nature of
CREBBP/p300 makes them ideal targets for the development of small
molecule tools that probe the role of an individual domain in overall
protein function.</p>
            <sec id="sec7.1.1">
               <title><italic toggle="yes">N</italic>-Acetylated Fragments</title>
               <p>Zhou et al.
reported early work toward identifying small molecule ligands for
the CREBBP bromodomain.<xref rid="ref83" ref-type="bibr"/> Having solved
the NMR structure of CREBBP bound to p53,<xref rid="ref8" ref-type="bibr"/> this group initiated a structure-based screening program, which
identified 14 bromodomain-binding compounds, two of which, <bold>24</bold> (MS2126) and <bold>25</bold> (MS7972) (Figure <xref rid="fig5"/>), were shown to block
the interaction between p53 and CREBBP in a concentration-dependent
manner. Additionally, in cells with doxorubicin-stimulated DNA damage,
both <bold>24</bold> and <bold>25</bold> suppressed the levels of
p53 and the expression of p21 (a target of p53). Further characterization
using an FA assay determined <bold>25</bold> to bind with a <italic toggle="yes">K</italic><sub>D</sub> of ∼20 μM. An NMR structure of <bold>25</bold> bound to CREBBP was solved suggesting that, although the
compound partly resided in the KAc binding site, no interactions were
formed with the highly conserved asparagine residue (N1168).</p>
            </sec>
            <sec id="sec7.1.2">
               <title>Azobenzene-Based
CREBBP Bromodomain Ligands</title>
               <p>In a subsequent
NMR screen the Zhou group identified a range of azobenzene-based CREBBP
bromodomain ligands.<xref rid="ref56" ref-type="bibr"/> A number of analogues
based on this framework were synthesized and screened in a cell-based
assay measuring p53-dependent expression of p21 in response to doxorubicin.
The optimized compound <bold>27</bold> (Figure <xref rid="fig5"/>) had an IC<sub>50</sub> value of 5 μM in the cellular assay
and a <italic toggle="yes">K</italic><sub>D</sub> value of 19 μM in a complementary
FA screen, and was up to 5-fold selective over the PCAF, BRD4(1),
and BAZ2B bromodomains. Treatment of cardiomyocytes with <bold>27</bold> prevented p53-induced apoptosis upon doxorubicin treatment, which
is a model for ischemic stress, leading to <bold>27</bold> being named
ischemin.</p>
            </sec>
            <sec id="sec7.1.3">
               <title>CREBBP Bromodomain-Binding Cyclic Peptide</title>
               <p>In addition
to their small molecule work, the Zhou group also developed a cyclic
peptide inhibitor of CREBBP, based on the CREBBP-binding sequence
of p53.<xref rid="ref84" ref-type="bibr"/> Molecular dynamics (MD) simulations
were employed to identify which residues in p53 could be converted
to cysteine and chemically linked, while still maintaining the β-turn
adopted by the bound peptide. Optimization of the amino acid sequence
and linker strategy resulted in the cyclic peptide <bold>26</bold> (Figure <xref rid="fig5"/>) that bound CREBBP with 8 μM
affinity. This affinity compares favorably with that of the native
p53 peptide (190 μM). Treatment of colorectal carcinoma and
embryonic kidney cells with <bold>26</bold> showed a reduction in
p53-induced p21 expression, consistent with the role of CREBBP bromodomain
binding in p53 activity.</p>
            </sec>
            <sec id="sec7.1.4">
               <title>Dihydroquinoxalinone-Based CREBBP Bromodomain
Ligands</title>
               <p>Rooney et al. developed a range of dihydroquinoxalinone-based
CREBBP
bromodomain inhibitors with submicromolar affinity.<xref rid="ref85" ref-type="bibr"/> The 3,4-dihydro-3-methyl-2­(1<italic toggle="yes">H</italic>)-quinazolinone
(DHQ) fragment was initially selected as the KAc mimic to be elaborated
to give potent CREBBP bromodomain ligands. However, as work in the
same group had shown that the DHQ moiety can undergo oxidation,<xref rid="ref37" ref-type="bibr"/> modification of the KAc mimic to the benzoxazinone
and dihydroquinoxalinone motifs was investigated. The dihydroquinoxalinone-based
compounds were potent ligands for the CREBBP bromodomain, displaying
submicromolar affinity in an AlphaScreen assay. X-ray crystallography
revealed that the tetrahydroquinoline appended to the dihydroquinoxalinone
KAc mimic (<bold>28</bold>, Figure <xref rid="fig5"/>) formed
a cation−π interaction with R1173 (Figure <xref rid="fig6"/>D). Computational studies indicated that this interaction
can form spontaneously in water and contributes toward the binding
affinity of the ligand for the bromodomain. The highest affinity compound
(<bold>28</bold>) displays modest selectivity for the CREBBP bromodomain
over BRD4(1) but showed good activity in a FRAP assay in U2OS cells.</p>
            </sec>
            <sec id="sec7.1.5">
               <title>3,5-Dimethylisoxazole-Based CREBBP Bromodomain Ligands</title>
               <p>During
the development of 3,5-dimethylisoxazole-based BET bromodomain
inhibitors, a number of compounds were observed to show some affinity
for the CREBBP bromodomain.<xref rid="ref37" ref-type="bibr"/> A carboxylic
acid-containing compound, <bold>29</bold> (Figure <xref rid="fig5"/>), showed the greatest affinity for the CREBBP bromodomain,
with an IC<sub>50</sub> value of 32 μM; it had similar potencies
for BET bromodomains. A crystal structure of <bold>29</bold> bound
to the CREBBP bromodomain confirmed that the 3,5-dimethylisoxazole
moiety acted as the KAc mimic, as was observed with the BRD4(1) bromodomain.
The carboxylate was postulated to form a long-range ionic interaction
with R1173, potentially contributing to this compound’s affinity
for the CREBBP bromodomain. A similar interaction between a sulfonate
group and R1173 was observed by Borah et al.<xref rid="ref56" ref-type="bibr"/> giving an indication that this residue might be important for CREBBP
bromodomain affinity.</p>
               <p>The optimization of nonselective 3,5-dimethylisoxazole-based
BET and CREBBP bromodomain ligands<xref rid="ref44" ref-type="bibr"/> resulted
in the development of SGC–CBP30 (<bold>30</bold>), which has
a <italic toggle="yes">K</italic><sub>D</sub> value of 21 nM (ITC) for CREBBP and
40-fold selectivity over BRD4(1).<xref rid="ref45" ref-type="bibr"/> The
selectivity of <bold>30</bold> over BRD4(1) remained a challenge throughout
the development of this compound. In the final compound, substitutions
of a morpholine and aryl group at the N(1) and C(2) positions of the
benzimidazole core, respectively, conveyed the desired selectivity
for the CREBBP bromodomain over the BET BCPs. The morpholine group
was directed into the ZA channel, while the aryl substituent formed
a cation−π interaction with R1173 (Figure <xref rid="fig6"/>E), consistent with the findings of Rooney et al. Using a
FRAP assay, <bold>30</bold> was shown to disrupt the binding of the
CREBBP bromodomain with chromatin in a cellular setting. In a luciferase-based
reporter assay, <bold>30</bold> inhibited the CREBBP-dependent expression
of p53 target genes. This compound is likely to be a valuable probe
in determining the role of the bromodomain in the complex functions
of CREBBP and p300, although it remains to be seen whether 40-fold
selectivity over the BET bromodomains is sufficient to avoid the strong
BET phenotype in a cellular setting.</p>
            </sec>
            <sec id="sec7.1.6">
               <title>Benzoxazepine-Based CREBBP
Ligand</title>
               <p>A CREBBP bromodomain
ligand based on a third chemotype has been developed by the SGC and
GSK. I-CBP112 (<bold>31</bold>) is a benzoxazepine-based CREBBP ligand
that binds to the bromodomains of CREBBP and EP300 with <italic toggle="yes">K</italic><sub>D</sub> values of 151 and 625 nM (ITC), respectively.<xref rid="ref86" ref-type="bibr"/> Selectivity over a range of other bromodomains
(ATAD2, BAZ2B, BRD2(2), BRD4 (1), PB1(5), PCAF, PHIP(2), and TIF1α)
appears satisfactory as determined by bilayer interferometry (BLI).
Compound <bold>31</bold> was active in a FRAP assay in U2OS cells,
indicating that it has on-target effects in a cellular setting. Although
the design of <bold>31</bold> is yet to be published, a structure
of <bold>31</bold> bound to the CREBBP bromodomain is available in
the PDB that reveals a number of interesting features. The benzoxazapine
core binds across the entrance to the KAc pocket, while the acyl group
attached to N(4) acts as the KAc mimic forming a direct hydrogen bond
to N1168 and water-mediated hydrogen bond to Y1125. The aryl group
at C(7) interacts with R1173 (Figure <xref rid="fig6"/>F) and
the two methoxy substituents suggest that this interaction was optimized
during the design process.</p>
               <fig id="fig6" position="float" orientation="portrait">
                  <label>6</label>
                  <caption>
                     <p>Comparison of the KAc mimicking groups in compounds <bold>28</bold> (A), <bold>30</bold> (B), and <bold>31</bold> (C) binding
to the
KAc binding pocket of the CREBBP bromodomain. Many of the residues
that form the KAc-binding pocket have been omitted for clarity. This
pocket is much more enclosed than implied by the representations above.
A comparison of the ligands <bold>28</bold> (D), <bold>30</bold> (E),
and <bold>31</bold> (F) interacting with R1173.</p>
                  </caption>
                  <graphic xlink:href="cb-2014-00996u_0006.tif"
                           id="gr6"
                           position="float"
                           orientation="portrait"/>
               </fig>
               <p>Despite relatively few ligands for the CREBBP bromodomain
being
published, each compound possesses a different KAc mimic. As with
the BET bromodomain ligands, the number of hydrogen bonds formed to
N1168 does not appear to affect compound affinity, and hydrophobic
interactions appear most significant.</p>
            </sec>
         </sec>
      </sec>
      <sec id="sec8">
         <title>Ligands for Other
Bromodomains</title>
         <sec id="sec8.1">
            <title>Pan-Bromodomain Ligands</title>
            <p>The SGC have reported a range
of [1,2,4]­triazolo­[4,3-<italic toggle="yes">a</italic>]­phthalazine-based compounds
(e.g., <bold>35</bold>) that act as nonselective bromodomain ligands,
with high affinity for BRD4(1), BRD9, and CREBBP.<xref rid="ref87" ref-type="bibr"/> These compounds are structurally similar to those disclosed
by GSK<xref rid="ref88" ref-type="bibr"/> and Constellation Pharmaceuticals<xref rid="ref89" ref-type="bibr"/> in patents from 2011 and 2012. Further work
on this chemotype resulted in the broad-spectrum bromodomain inhibitor,
bromosporine (<bold>36</bold>), named with reference to the nonselective
kinase inhibitor, staurosporine.<xref rid="ref90" ref-type="bibr"/> Details
on the development of this compound have yet to be published; however,
DSF shows that the compound displayed Δ<italic toggle="yes">T</italic><sub>m</sub> ≥ 3.0 °C at 10 μM for the bromodomains
of BRD2(1), BRD3(1), BRD4(1), BRDT(1), CECR2, TAF1(2), BRD9, and CREBBP.<xref rid="ref91" ref-type="bibr"/> Bromosporine showed good cellular activity,
with moderate cytotoxicity in HeLa cells at 18 μM. This compound
will likely be useful as a tool for probing bromodomains for which
no other ligands are known.</p>
            <fig id="fig7" position="float" orientation="portrait">
               <label>7</label>
               <caption>
                  <p>Structures of bromodomain inhibitors for a range
of non-BET or
CREBBP bromodomains and their IC<sub>50</sub> or <italic toggle="yes">K</italic><sub>D</sub> values with the method used to obtain these values.
The KAc-mimicking component of the molecule, as determined by X-ray
crystallography, is shown in red where known.</p>
               </caption>
               <graphic xlink:href="cb-2014-00996u_0007.tif"
                        id="gr7"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>Ferguson et al. identified a range of BAZ2B bromodomain-binding
fragments that were subsequently optimized, the highest affinity optimized
compound is shown in Figure <xref rid="fig7"/> (<bold>33</bold>).<xref rid="ref92" ref-type="bibr"/> X-ray crystal structures of four
fragments bound to the BAZ2B bromodomain were obtained, providing
insight into the development of higher affinity ligands for this bromodomain.
GSK and the SGC have developed a high-affinity probe for the BAZ2A/B
bromodomains, GSK2801 (<bold>32</bold>, Figure <xref rid="fig7"/>), which is reported on the SGC website.<xref rid="ref93" ref-type="bibr"/> This compound has <italic toggle="yes">K</italic><sub>D</sub> values of 136 and
257 nM (ITC) for the BAZ2B and BAZ2A bromodomains, respectively. The
SGC website also reports another BAZ2A/B bromodomain probe that was
developed in collaboration with the Institute of Cancer Research.
This compound, known as BAZ2-ICR, binds to BAZ2A with a <italic toggle="yes">K</italic><sub>D</sub> value of 109 nM (ITC) and to BAZ2B with a <italic toggle="yes">K</italic><sub>D</sub> value of 170 nM (ITC).</p>
            <p>Pfizer and the SGC have
collaborated to develop a ligand (PFI-3, <bold>34</bold>, Figure <xref rid="fig7"/>) for the SMARCA4 bromodomain,
with a <italic toggle="yes">K</italic><sub>D</sub> value of 89 nM (ITC). Compound <bold>34</bold> also binds to the fifth bromodomain of polybromodomain-containing
protein 1 [PB1(5)] with a <italic toggle="yes">K</italic><sub>D</sub> value of
48 nM (ITC).<xref rid="ref94" ref-type="bibr"/></p>
         </sec>
      </sec>
      <sec id="sec9">
         <title>Evaluation of the Assays
Available to Study Bromodomain Inhibition
in Fragment Based Methodologies</title>
         <sec id="sec9.1">
            <title><italic toggle="yes">In Silico</italic> Approaches</title>
            <p>Computational
techniques offer qualitative and quantitative means to interrogate
structures and dynamics associated with small molecule binding to
bromodomains, using atomistic simulations.<xref rid="ref95" ref-type="bibr"/> In recent years, the availability of high-resolution crystal structures
of bromodomains combined with molecular dynamics (MD),<named-content content-type="bibref-group"><xref rid="ref85" ref-type="bibr"/>,<xref rid="ref96" ref-type="bibr"/></named-content> docking,<xref rid="ref24" ref-type="bibr"/> and quantum mechanical (QM)
calculations has been used to explore the mechanisms of epigenetic
reading and inhibition. MD simulation provides insight into the binding
of small molecules to bromodomains, capturing the effects of conformational
flexibility (of both macromolecule and ligand) and of explicitly described
water molecules. These are demanding calculations, and the underlying
computational description is typically rooted in molecular mechanics
(MM) methods-based classical force fields. Results are thus contingent
upon the quality of force field parameters used and on ensuring effective
conformational sampling. The reduced cost of MM versus QM based approaches
has resulted in its extensive use for the understanding of the binding
of small molecules in bromodomains, focusing on docking and molecular
dynamics (MD) studies.<named-content content-type="bibref-group"><xref rid="ref97" ref-type="bibr"/>−<xref rid="ref98" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref99" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref100" ref-type="bibr"/></named-content></p>
            <p>MD has been applied to the understanding of the PPIs formed
by bromodomains. Carloni and co-workers<xref rid="ref101" ref-type="bibr"/> have studied the protein–protein interface of the PCAF/Tat-K50Ac
complex to understand the most important residues involved in binding.
Simulation (Amber ff94, 8.4 ns of NPT) showed that the binding interface
is predominantly hydrophobic and the replacement of Y760 and Y761
by hydrophilic residues through mutations resulted in blocking of
PCAF/Tat complex formation. Poplawski and co-workers<xref rid="ref97" ref-type="bibr"/> performed MD simulations (Amber ff99SB, 10 ns of NPT) alongside
experimental studies to evaluate the binding of different histone
peptides to BRPF1 bromodomain. Preferential binding was observed with
peptides H2AK5Ac, H4K12Ac, and H3K14Ac, and the order of binding free
energies was well reproduced by an MM/PBSA analysis of the MD simulation
data. Binding is due to a network of hydrogen bond contacts: for the
strongest binder, these interactions were observed in more than 90%
of the trajectory. Zhou and co-workers<xref rid="ref23" ref-type="bibr"/> performed Monte Carlo simulations to analyze the importance of water
solvation, showing that the displacement of a weakly bound water molecule
in the KAc binding site of PCAF resulted in more potent <italic toggle="yes">N</italic>1-arylpropane-1,3-diamine analogues.</p>
            <p>Filippakopoulos and co-workers<xref rid="ref24" ref-type="bibr"/> explored
the binding of (±)-JQ1 (<bold>3</bold>, Figure <xref rid="fig2"/>) to BET bromodomains BRD4 and BRD2. Using adapted ChemScore
functions<xref rid="ref102" ref-type="bibr"/> for docking calculations,
they showed that only (+)-JQ1 (<bold>3</bold>) bound BRD4 and BRD2,
being stabilized by hydrophobic interactions with conserved BET residues
in the ZA- and BC-loop regions, corroborating the crystallographically
determined binding mode (PDB IDs: <ext-link ext-link-type="pdb" xlink:href="3MXF"/><xref rid="ref14" ref-type="bibr"/> and <ext-link ext-link-type="pdb" xlink:href="3ONI"/><xref rid="ref24" ref-type="bibr"/>). MD simulation (Amber ff03, 20 ns) showed that (+)-JQ1
reduces the flexibility of the BRD4 and BRD2 loops, stabilizing the
KAc binding cavity. Rooney et al.<xref rid="ref85" ref-type="bibr"/> synthesized
a series of dihydroquinoxalinone-based CREBBP ligands.<xref rid="ref85" ref-type="bibr"/> Through docking studies<xref rid="ref103" ref-type="bibr"/> and MD simulations (Amber ff99SB, 100 ns NPT), key interactions
were observed between these derivatives and the KAc binding site of
the CREBBP bromodomain: dual hydrogen bonds are formed by the dihydroquinoxalinone
group with residue N1168, while a cation−π interaction
also exists with R1173.<xref rid="ref85" ref-type="bibr"/> Caflisch and
co-workers<xref rid="ref104" ref-type="bibr"/> have investigated the importance
of structured water molecules for KAc binding in BAZ2B and CREBBP,
with MD simulation (CHARMM PARAM22 force field,<xref rid="ref105" ref-type="bibr"/> 500 ns NPT) in the presence of dimethyl sulfoxide (DMSO)
or alcohol cosolvents. They observed that most of the structured water
molecules at the bottom of the KAc binding pocket were transiently
displaced by alcohol solvents.</p>
            <fig id="fig8" position="float" orientation="portrait">
               <label>8</label>
               <caption>
                  <p>BET bromodomain-binding fragments. The
structures of BET bromodomain-binding
fragments reported by Vidler (<bold>37</bold>–<bold>40</bold>)<xref rid="ref106" ref-type="bibr"/> and Zhao (<bold>41</bold>–<bold>44</bold>).<xref rid="ref100" ref-type="bibr"/> The KAc-mimicking component
of the molecule, as determined by X-ray crystallography, is shown
in red where known.</p>
               </caption>
               <graphic xlink:href="cb-2014-00996u_0008.tif"
                        id="gr8"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>Docking studies offer
a much faster means to study and predict
important ligand–protein interactions than by MD simulation,
encouraging their use in the development of fragment-based libraries.
Starting from a large library of more than 9000 compounds, Caflisch
and co-workers<xref rid="ref100" ref-type="bibr"/> developed a new fragment-based
high-throughput docking approach, called ALTA, to select 24 compounds
for biological testing to identify four compounds (<bold>41</bold>–<bold>44</bold>) that were observed to bind BRD4(1) using
DSF (Figure <xref rid="fig8"/>).<xref rid="ref100" ref-type="bibr"/></p>
            <p>Vidler et al. took a virtual screening approach to identify
predicted
BRD4(1)-binding fragments. In this work they tested 143 compounds
that were predicted to bind to the KAc-binding pocket of BRD4(1).
From an AlphaScreen analysis of these compounds, six novel hit compounds
were identified, four of which (<bold>37</bold>–<bold>40</bold>) were based on unprecedented KAc-mimicking groups (Figure <xref rid="fig8"/>). These four compounds have RMMs of between 245
and 363; they showed low micromolar IC<sub>50</sub> values against
BRD4(1) and possess ligand efficiencies of 0.27–0.31. Muvva
et al. used an <italic toggle="yes">in silico</italic> approach to screening compounds
from the NCI Diversity, Drug Bank, and Toslab databases for predicted
BRD4(1) affinity.<xref rid="ref98" ref-type="bibr"/> Although a number of
predicted ligands were identified, no experimental evidence for BRD4(1)
binding was presented. Specific adaptations to the docking of protein–peptide
complexes are necessary to account for the higher conformational flexibility
of the peptide molecule, as in the HADDOCK approach.<xref rid="ref107" ref-type="bibr"/> Ferguson and co-workers<xref rid="ref108" ref-type="bibr"/> performed
data-driven docking on the basis of experimentally determined chemical
shift perturbation data and, in conjunction with MD simulation (AMBER99SB-STAR-ILDNR,
225 ns), have characterized the structure and dynamics of histone
binding to the BAZ2B bromodomain. Not only residues in the KAc binding
site but also in the BC loop were identified as binding hotspots.</p>
            <p>Docking and MD studies have been useful tools to support the discovery
of new bromodomain inhibitors.<named-content content-type="bibref-group"><xref rid="ref24" ref-type="bibr"/>,<xref rid="ref85" ref-type="bibr"/>,<xref rid="ref98" ref-type="bibr"/></named-content> However, the design of potent and selective inhibitors remains challenging,<xref rid="ref95" ref-type="bibr"/> due to the structural similarities among KAc
binding sites across BET and non-BET families, increasing the importance
of using computational approaches to analyze the key differences between
these proteins. Hoelder and co-workers<xref rid="ref109" ref-type="bibr"/> have used SiteMap,<named-content content-type="bibref-group"><xref rid="ref110" ref-type="bibr"/>,<xref rid="ref111" ref-type="bibr"/></named-content> a software that combines binding
site identification with druggability assessment, to separate 105
crystal structure entries available in the PDB as druggable or undruggable
targets based on physicochemical properties as size, degree of enclosure
by the protein, hydrophilicity, and hydrophobicity. They classified
BET bromodomains as highly druggable, while CREBPP was considered
to have intermediate druggability. Although the SiteMap approach discards
the flexibility of bromodomains,<xref rid="ref112" ref-type="bibr"/> this
technique shows that BET bromodomains and CREBBP are interesting targets
for the development of more potent inhibitors, as reported in the
literature.<named-content content-type="bibref-group"><xref rid="ref85" ref-type="bibr"/>,<xref rid="ref95" ref-type="bibr"/>,<xref rid="ref113" ref-type="bibr"/></named-content> Aiming to facilitate the search for new inhibitors of epigenome
reader domains, including bromodomains, Zhou and co-workers<xref rid="ref114" ref-type="bibr"/> have developed ChEpiMod, a knowledgebase of
information from papers and public databases relating to drug binding
in reader proteins, from which binding affinities and protein–ligand
interactions may be derived.</p>
            <p>The underlying physical basis of
small molecule binding to bromodomains
may be difficult to describe accurately through classical simulations
(e.g., docking and MD studies), as a result of the parameters used
and the classical description of, e.g., hydrogen-bonding and other
non-bonding interactions, e.g., π–π and cation−π
interactions.<named-content content-type="bibref-group"><xref rid="ref115" ref-type="bibr"/>,<xref rid="ref116" ref-type="bibr"/></named-content> QM calculations, although more
costly, provide descriptions of these key interactions with less empiricism
and greater accuracy. For example, the interaction of compound <bold>28</bold> with the CREBBP KAc binding site displays a critical cation−π
interaction between its aromatic side chain and a positively charged
arginine residue.<xref rid="ref85" ref-type="bibr"/> Density functional
theory (DFT) calculations estimate the strength of this attractive
cation−π interaction to be in the region of 3.2–4.7
kcal mol<sup>–1</sup>, consistent with experimentally measured
average strengths of such interactions involving lysine (−3.3
± 1.5 kcal mol<sup>–1</sup>) or arginine (−2.9
± 1.4 kcal mol<sup>–1</sup>).<xref rid="ref115" ref-type="bibr"/> Mirguet and co-workers<xref rid="ref113" ref-type="bibr"/> have used QM
calculations to understand the biological activity of naphthyridine
derivatives inside BRD2 since docking approaches were unable to account
for the lower potency of 1,6-naphthyridine derivatives compared to
isoxazoloquinolines. Stronger binding was observed when the DFT-computed
gas-phase conformation was similar to the nonplanar bound conformation,
as seen for the quinoline series. The 1,6-naphthyridine derivatives
favor a planar conformation in the gas phase, resulting in lower bromodomain
affinities.</p>
            <p>Ongoing theoretical and computational developments
such as the
improvement of docking scoring functions and the inclusion of active
site water molecules, the ability to perform long time scale MD simulations
through advances in hardware and software, and increases in accurate
QM computation of interaction energies will ensure that computational
approaches are important tools in the development of bromodomain ligands.</p>
         </sec>
         <sec id="sec9.2">
            <title><italic toggle="yes">In Vitro</italic> Assays Available to Study Bromodomain–Ligand
Interactions</title>
            <p>The availability of a range of assays to identify
bromodomain inhibitors has been crucial to the rapid progress in this
field. For details of techniques that have been employed in the identification
and optimization of bromodomain ligands, we refer readers to the extensive
literature on this subject,<named-content content-type="bibref-group"><xref rid="ref117" ref-type="bibr"/>−<xref rid="ref118" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref119" ref-type="bibr"/></named-content> including a review summarizing
the techniques in the context of bromodomains, and more recent papers
outlining their optimization.<named-content content-type="bibref-group"><xref rid="ref38" ref-type="bibr"/>,<xref rid="ref120" ref-type="bibr"/></named-content> Validation of assays
for proteins without enzymatic ability is challenging, particularly
when binding partners are not well established. However, combinations
of biophysical assays have successfully enabled characterization of
lead molecules, leading to improvements in affinity and selectivity.
Furthermore, trends in assay utility highlight several key points
for obtaining and interpreting these data.</p>
            <p>Label free methods
shaped the field before native binding partners had been characterized:
the first small molecule inhibitors of bromodomains were discovered
through NMR-based chemical screening monitoring 2D <sup>15</sup>N
HSQC spectra;<xref rid="ref83" ref-type="bibr"/> operationally simple DSF
assays allow rapid progression to screening platforms and have been
used throughout;<xref rid="ref24" ref-type="bibr"/> SPR has primarily been
used as a secondary assay for hit validation.<named-content content-type="bibref-group"><xref rid="ref29" ref-type="bibr"/>,<xref rid="ref38" ref-type="bibr"/></named-content> Subsequently, pull down assays demonstrated that bromodomains bound
to acetylated histones, elucidating the role of bromodomains in KAc
recognition and binding.<xref rid="ref121" ref-type="bibr"/> The understanding
led to several assays based on displacement of a known binding partner,
often a histone-based modified peptide. These assays require use of
a competitor peptide with sufficient affinity to enable signal detection.
Studies have shown improved signal-to-noise ratios and increased accuracy
of quantification after optimization of competitor peptides<xref rid="ref52" ref-type="bibr"/> or choice of buffer.<xref rid="ref122" ref-type="bibr"/> With the advantage of high-throughput and low resource requirements,
AlphaScreen is frequently used as a primary screening method, despite
a high rate of artifacts.<xref rid="ref92" ref-type="bibr"/> ITC is still
considered the “gold standard” for quantifying binding
affinity,<xref rid="ref123" ref-type="bibr"/> directly measuring thermodynamic
contributions to affinity, and has frequently been used to characterize
affinities of both peptides<xref rid="ref124" ref-type="bibr"/> and novel
ligands<xref rid="ref59" ref-type="bibr"/> and to determine selectivities
of ligands between bromodomains.</p>
            <p>Some of the earliest work in
this field focused on the PCAF/Tat-K50Ac
interaction, which had been implicated in HIV,<xref rid="ref22" ref-type="bibr"/> including the first assay used to quantify binding affinities
to a bromodomain: an ELISA after NMR based chemical screening.<xref rid="ref125" ref-type="bibr"/> Subsequently, FA has been used for identification
and evaluation of pyridine 1-oxide derivatives as inhibitors of the
PCAF bromodomain, with IC<sub>50</sub> values that correlate to <italic toggle="yes">in vitro</italic> anti-HIV-1 activity.<xref rid="ref122" ref-type="bibr"/> FA-based assays previously developed for BET bromodomains by GSK
provided a robust, low-resource, and sensitive platform able to identify
weak fragment hits<xref rid="ref51" ref-type="bibr"/> and to characterize
naphthyridines as BET bromodomain inhibitors.<xref rid="ref113" ref-type="bibr"/></p>
            <p>Cellular activity has been important for both fundamental
studies
into natural recognition modes of bromodomains and demonstration of
therapeutic potential for targets of probe compounds. Visualization
of histone binding by BET proteins in cells was first achieved by
FRET combined with flow cytometry to assess selectivity.<xref rid="ref126" ref-type="bibr"/> The ability of (+)-JQ1 (<bold>3</bold>, Figure <xref rid="fig2"/>) to compete with histone binding in a cellular
environment was established through FRAP.<xref rid="ref24" ref-type="bibr"/> Following identification by DSF and IC<sub>50</sub> determination
by AlphaScreen, the ability of triazolophthalazine bromodomain inhibitors
to displace CREBBP from chromatin in cells was also assessed using
FRAP.<xref rid="ref87" ref-type="bibr"/> Since then, a cell-based FRAP assay
has demonstrated the cellular efficacy of inhibitors of a diverse
set of bromodomain targets.<xref rid="ref127" ref-type="bibr"/> It should
be noted that the CREBBP bromodomain had to be adapted due to high
contributions from other domains to chromatin binding: three repeating
units of the bromodomain were multimerised in isolation, resulting
in a cellular assay useful for inhibitor development but not full
target validation.</p>
            <p>Most successful campaigns have been characterized
by tiered complementary
screening methods, to enable fast identification and validation of
hits. Even within techniques, assay protocols may differ significantly
due to differences in protein and detection parameters; hence, SAR
analysis is often best performed within a single comparative set,
which is subjected to the same conditions.<xref rid="ref39" ref-type="bibr"/> Alternatively, complementary sets of data can be used for comprehensive
compound characterization: reported affinities of (+)-JQ1 (<bold>3</bold>, Figure <xref rid="fig2"/>) to BRD4(1) include <italic toggle="yes">K</italic><sub>D</sub> 14.5 ± 3.3 nM (FA), Δ<italic toggle="yes">T</italic><sub>m</sub> 9.6 ± 0.6 °C (DSF), <italic toggle="yes">K</italic><sub>D</sub> 1.0 nM (DSF), <italic toggle="yes">K</italic><sub>D</sub> 105.7 ± 13.9 nM
(TR-FRET),<xref rid="ref128" ref-type="bibr"/> <italic toggle="yes">K</italic><sub>D</sub> 49.0 ± 2.4 nM (ITC), IC<sub>50</sub> 76.9 ± 1.7 nM (AlphaScreen),
and Δ<italic toggle="yes">T</italic><sub>m</sub> 9.4 ± 0.07 °C
(DSF).<xref rid="ref24" ref-type="bibr"/></p>
            <p>Commercial screening capacity
has been utilized by several groups
to provide information on affinity and selectivity. DiscoveRx offers
a service of 40 screening-ready, quantitative binding bromodomain
assays in BROMO<italic toggle="yes">scan</italic>,<named-content content-type="bibref-group"><xref rid="ref71" ref-type="bibr"/>,<xref rid="ref129" ref-type="bibr"/>,<xref rid="ref130" ref-type="bibr"/></named-content> including the ability to compare a selectivity profile
to previously screened compounds. Cellular effects of two clinical
kinase inhibitors demonstrating nanomolar affinity against bromodomains
were assessed in a 12 primary human cell-based BioMAP system, used
to suggest the viability of discovering potent and selective drugs
with polypharmacologies. Results from their latest cell-based bromodomain
assays, EPI<italic toggle="yes">scan</italic>, have yet to be seen in the literature.</p>
            <p>Overall, the field demonstrates the importance of determining target
protein binding early in the ligand identification process using direct
assays in which a signal is generated directly from the interaction
between a ligand and target. Further characterization and optimization
of ligand binding can be achieved using indirect assays, which provide
information on the displacement of competitor ligands with a known
binding site. Activity and selectivity can then be confirmed by combinations
of biophysical and cellular assays, including screening panels and
direct assay techniques such as ITC.</p>
         </sec>
      </sec>
      <sec id="sec10">
         <title>Clinical Applications</title>
         <p>While assays provide the fundamental tools for compound identification
and development, therapeutic applications can only be confirmed after
progression to clinical models and trials. Promising effects of BET
bromodomain ligands have been observed in a range of pathologies,
sometimes attributed to the ability of bromodomain inhibitors to interfere
in cell state regulation rather than a specific state itself,<named-content content-type="bibref-group"><xref rid="ref131" ref-type="bibr"/>−<xref rid="ref132" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref133" ref-type="bibr"/></named-content> via mediation of superenhancers, which both drive expression to
define cell identity and facilitate cell state transitions during
development.</p>
         <p>The first study to demonstrate the efficacy of
a bromodomain inhibitor
in a preclinical cancer model investigated the effect of (+)-JQ1 on
mice bearing a NUT midline carcinoma (NMC) xenograft, a rare but highly
aggressive form of cancer driven by the BRD4-NUT oncoprotein. (+)-JQ1
(<bold>3</bold>) treatment resulted in a reduction of tumor volume
and promoted survival, at doses that had minimal toxicity to normal
tissues.<xref rid="ref24" ref-type="bibr"/></p>
         <p>(+)-JQ1 has been used
in genetically engineered mouse model and
patient-derived Hedgehog driven tumors as a strategy to control oncogenesis
in several cancers.<xref rid="ref134" ref-type="bibr"/> Compound <bold>3</bold> has also recently revealed a novel epigenetic approach for the concerted
inhibition of oncogenic drivers in advanced prostate cancer, which
currently has a low number of therapeutic options.<xref rid="ref135" ref-type="bibr"/> Treatment of osteosarcoma cells with (+)-JQ1 reduces cell
viability and bone tumor development both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>.<xref rid="ref136" ref-type="bibr"/> A study
of metabolic alterations during oncogenesis of glioblastoma multiforme
cells considered (+)-JQ1 essentially as an inhibitor of Myc expression,
a highly upregulated pathogenic protein found in many cancers. Upon
treatment, cell proliferation was uniformly inhibited in 25 multiple
myeloma cell lines, and an investigational study of treatment in orthotopic
mouse models of advanced disease demonstrated a decrease in systematic
burden and significant prolongation in overall survival.<xref rid="ref137" ref-type="bibr"/></p>
         <p>I-BET762 (<bold>1</bold>, Figure <xref rid="fig2"/>) is currently
undergoing two Phase 1 clinical trials, one for NUT midline carcinoma
(ClinicalTrials.gov identifier: NCT01587703) and the other for relapsed
refractory hematological malignancies (ClinicalTrials.gov identifier:
NCT01943851).</p>
         <p>I-BET151 (<bold>11</bold>) showed broad anti-inflammatory
properties
and demonstrated profound efficacy against human and murine MLL-fusion
leukemic cell lines, via induction of early cell cycle arrest and
apoptosis. More recently, I-BET151 was shown to selectively regulate
IL-6 production.<xref rid="ref138" ref-type="bibr"/> In a chronic model
of inflammation involving IL-6, experimental autoimmune encephalomyelitis
(EAE), which is extensively used as a model of multiple sclerosis,
mice treated with I-BET-151 demonstrated a significant delay in the
onset of clinical symptoms and a reduced maximal severity of EAE.</p>
         <p>Clinical trials on RVX-208 (<bold>7</bold>) were initiated based
on its ability to modulate ApoA1 levels prior to it being identified
as a BET bromodomain ligand. The first indications investigated the
effect of the compound on atherosclerosis (ClinicalTrials.gov identifier:
NCT01058018) and coronary artery disease (ClinicalTrials.gov identifier:
NCT01067820). This trial failed to meet its primary end point, but
it did show that RVX-208 caused a modest regression of coronary atherosclerosis
and that a synergistic effect was observed when administered in combination
with Rosuvastatin. It is not entirely clear that the effects of BET
bromodomain ligands modulate ApoA1 levels by direct interaction with
BET bromodomains, and further studies are needed in this area.<xref rid="ref13" ref-type="bibr"/> Trials focusing on the effect of RVX-208 on
dyslipidemia (ClinicalTrials.gov identifier: NCT01423188) and type
II diabetes (ClinicalTrials.gov identifier: NCT01728467) have also
been completed. Interestingly, analysis of the pooled data collected
in these trials revealed a statistically significant reduction of
major adverse cardiovascular events (MACE) in patients with diabetes
mellitus. Analysis of the pooled patient data showed again that RVX-208
treatment led to a statistically significant relative risk reduction
in MACE of &gt;65% compared to placebo. This finding is important
as
the majority of diabetes mellitus patients die from cardiovascular
diseases. Diabetes mellitus patients given RVX-208 tended to have
lower blood glucose compared to those patients given a placebo. In
diabetes mellitus patients who had low levels of high-density lipoprotein,
the blood glucose was significantly lower following treatment with
RVX-208 compared to placebo. It was noted that the time required for
RVX-208 to reduce blood glucose was at least 12 weeks following initiation
of treatment.</p>
         <p>Phase 1 clinical trials for the effect of OTX015
(<bold>5</bold>) in acute leukemia and other hematological malignancies
(ClinicalTrials.gov
identifier: NCT01713582) and selected solid tumors (ClinicalTrials.gov
identifier: NCT02259114) are currently recruiting. Trials are also
scheduled to assess the effect of OTX015 in patients with recurrent
glioblastoma multiform (ClinicalTrials.gov identifier: NCT02296476)
and the effect of OTX015, in combination with azacitidine, in patients
with acute myeloid leukemia (ClinicalTrials.gov identifier: NCT02303782).</p>
      </sec>
      <sec id="sec11">
         <title>Conclusion</title>
         <p>Above we have outlined the extraordinary progress that has been
made in the development and application of bromodomain ligands. It
is significant that the first potent BET bromodomain ligands were
discovered using phenotypic screening, meaning that an observable
cellular phenotype for such ligands was assured. It is also significant
that the chemoproteomic studies conducted by GSK revealed that siRNA
knock down of one target, BRD4, recapitulated the phenotype produced
by the small molecule BET ligands.<xref rid="ref29" ref-type="bibr"/> Had
this work identified that complex polypharmacology was responsible
for the phenotype observed, it is unlikely that the rate of progress
would have been as rapid. In addition, the structural biology that
has underpinned the structure-guided work that followed would likely
not have happened. Thus, the work on BET bromodomains indicates that
phenotypic screening is an effective method for identifying first-in-class
ligands and that structure-guided design allows understanding of ligand
SAR and optimization of the ligand chemotype.</p>
         <p>The success in
developing BET bromodomain ligands has promoted
work to develop potent and selective ligands for other, non-BET, bromodomains.
Work on CREBBP, in particular, has demonstrated that this aim is achievable
and ligands are now emerging for further non-BET bromodomains, although
obtaining high selectivity for a given bromodomain remains a challenge.
This work has been extensively structure-guided, as the knowledge
gained in crystallizing the BET bromodomains has proved transferable
to over half of the other human bromodomains. The challenge now is
identifying and understanding the cellular changes that these ligands
evoke. However, it is clear that small molecule compounds are highly
valuable tools in probing the biology of bromodomain-containing proteins.
The continued development of such compounds is essential if we are
to further understand the function of bromodomain-containing proteins
and evaluate their potential as therapeutic targets.</p>
      </sec>
   </body>
   <back>
      <notes id="NOTES-d386e1798-autogenerated" notes-type="conflict-of-interest">
         <p>The authors declare no
competing financial interest.</p>
      </notes>
      <ack>
         <title>Acknowledgments</title>
         <p>M.B. thanks the Berrow Foundation for studentship support.
A.M. thanks Pfizer Neusentis and the EPSRC for studentship support.
B.W. thanks UCB and the BBSRC for studentship support. D.S.H. thanks
Cancer Research U.K. for studentship support. W.A.C. is supported
by a Science Without Borders (CAPES) scholarship. S.J.C. thanks St.
Hugh’s College, Oxford, for research support, and the BBSRC,
the EPSRC, GSK, Pfizer Neusentis, and UCB for supporting research
in the area of bromodomain ligands.</p>
      </ack>
      <glossary>
         <def-list id="dl1" specific-use="delimiter-char:, ">
            <title>Abbreviations</title>
            <def-item>
               <term>ApoA1</term>
               <def>
                  <p>apolipoprotein A1</p>
               </def>
            </def-item>
            <def-item>
               <term>BCP</term>
               <def>
                  <p>bromodomain-containing
protein</p>
               </def>
            </def-item>
            <def-item>
               <term>BET</term>
               <def>
                  <p>bromodomain
and extra terminal domain</p>
               </def>
            </def-item>
            <def-item>
               <term>CDK</term>
               <def>
                  <p>cyclin-dependent kinase</p>
               </def>
            </def-item>
            <def-item>
               <term>CREB</term>
               <def>
                  <p>cAMP response element binding protein (CREB) binding
protein (CREBBP)</p>
               </def>
            </def-item>
            <def-item>
               <term>DFT</term>
               <def>
                  <p>density functional theory</p>
               </def>
            </def-item>
            <def-item>
               <term>DHQ</term>
               <def>
                  <p>3,4-dihydro-3- methyl-2­(1<italic toggle="yes">H</italic>)-quinazolinone</p>
               </def>
            </def-item>
            <def-item>
               <term>DSF</term>
               <def>
                  <p>differential scanning
fluorimetry</p>
               </def>
            </def-item>
            <def-item>
               <term>ELISA</term>
               <def>
                  <p>enzyme-linked immunosorbent assay</p>
               </def>
            </def-item>
            <def-item>
               <term>FA</term>
               <def>
                  <p>fluorescence anisotropy</p>
               </def>
            </def-item>
            <def-item>
               <term>FRAP</term>
               <def>
                  <p>fluorescence recovery after photobleaching</p>
               </def>
            </def-item>
            <def-item>
               <term>FRET</term>
               <def>
                  <p>fluorescence resonance
energy transfer</p>
               </def>
            </def-item>
            <def-item>
               <term>HDAC</term>
               <def>
                  <p>histone deactylase</p>
               </def>
            </def-item>
            <def-item>
               <term>ITC</term>
               <def>
                  <p>isothermal titration calorimetry</p>
               </def>
            </def-item>
            <def-item>
               <term>KAc</term>
               <def>
                  <p>acetyl-lysine residues</p>
               </def>
            </def-item>
            <def-item>
               <term>KAT/HAT</term>
               <def>
                  <p>lysine/histone acetyltransferase</p>
               </def>
            </def-item>
            <def-item>
               <term>MD</term>
               <def>
                  <p>molecular dynamics</p>
               </def>
            </def-item>
            <def-item>
               <term>MM</term>
               <def>
                  <p>molecular mechanics</p>
               </def>
            </def-item>
            <def-item>
               <term>NMC</term>
               <def>
                  <p>NUT midline carcinoma</p>
               </def>
            </def-item>
            <def-item>
               <term>PI3K</term>
               <def>
                  <p>phosphoinositide
3-kinase</p>
               </def>
            </def-item>
            <def-item>
               <term>PPI</term>
               <def>
                  <p>protein–protein
interaction</p>
               </def>
            </def-item>
            <def-item>
               <term>PTEFB</term>
               <def>
                  <p>positive transcription elongation factor B</p>
               </def>
            </def-item>
            <def-item>
               <term>PTM</term>
               <def>
                  <p>protein post-translational modification</p>
               </def>
            </def-item>
            <def-item>
               <term>QM</term>
               <def>
                  <p>quantum mechanical</p>
               </def>
            </def-item>
            <def-item>
               <term>SPR</term>
               <def>
                  <p>surface plasmon
resonance</p>
               </def>
            </def-item>
         </def-list>
      </glossary>
      <glossary>
         <def-list id="dl2" specific-use="delimiter-char:: ">
            <title>Keywords</title>
            <def-item>
               <term><bold>Acetyl-lysine</bold></term>
               <def>
                  <p>Post-translational
acetylation of lysine results in acetyl-lysine, which has no charge
and hence a weaker association with negatively charged DNA. Acetyl-lysine
residues also bind to bromodomains</p>
               </def>
            </def-item>
            <def-item>
               <term><bold>BET</bold></term>
               <def>
                  <p>The bromodomain and
extra terminal domain family of bromodomain-containing proteins, comprising
BRD2–4 and BRDT</p>
               </def>
            </def-item>
            <def-item>
               <term><bold>BRD4</bold></term>
               <def>
                  <p>Bromodomain-containing
protein 4</p>
               </def>
            </def-item>
            <def-item>
               <term><bold>Bromodomain</bold></term>
               <def>
                  <p>A protein module
that mediates protein–protein interactions by binding to an
acetyl-lysine residue in the partner protein. Bromodomains are viewed
as epigenetic reader domains</p>
               </def>
            </def-item>
            <def-item>
               <term><bold>Chromatin</bold></term>
               <def>
                  <p>In eukaryotic
cells DNA is packaged around histone proteins to form a nucleosome
particle. Many nucleosome particles form a macromolecular complex
that is known as chromatin and in turn forms chromosomes</p>
               </def>
            </def-item>
            <def-item>
               <term><bold>Epigenetic</bold></term>
               <def>
                  <p>An
epigenetic
trait is generally recognized as a stably heritable phenotype resulting
in changes in a chromosome without alterations in the DNA sequence</p>
               </def>
            </def-item>
            <def-item>
               <term><bold>Probe</bold></term>
               <def>
                  <p>Typically a small
molecule that has well-characterized biological activity and has been
designed to interact with one target or a small number of targets.
Such molecules can be used <italic toggle="yes">in vitro</italic> or <italic toggle="yes">in
vivo</italic> and are powerful tools for understanding the role of
the target(s) in a more intact biological setting</p>
               </def>
            </def-item>
            <def-item>
               <term><bold>Reader</bold></term>
               <def>
                  <p>A protein domain
that binds to a defined post-translational modification on a partner
protein and hence mediates a protein–protein interaction</p>
               </def>
            </def-item>
         </def-list>
      </glossary>
      <ref-list>
         <title>References</title>
         <ref id="ref1">
            <element-citation publication-type="journal" id="cit1">
               <name name-style="western">
                  <surname>Allfrey</surname>
                  <given-names>V. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Faulkner</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mirsky</surname>
                  <given-names>A. E.</given-names>
               </name>
               <article-title>Acetylation
and methylation of histones
and their possible role in the regulation of RNA synthesis</article-title>
               <source>Proc. Natl. Acad. Sci. U.S.A.</source>
               <year>1964</year>
               <volume>51</volume>
               <fpage>786</fpage>
               <lpage>794</lpage>
            </element-citation>
         </ref>
         <ref id="ref2">
            <element-citation publication-type="journal" id="cit2">
               <name name-style="western">
                  <surname>Gershey</surname>
                  <given-names>E. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Vidali</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Allfrey</surname>
                  <given-names>V. G.</given-names>
               </name>
               <article-title>Chemical studies of histone acetylation</article-title>
               <source>J. Biol. Chem.</source>
               <year>1968</year>
               <volume>243</volume>
               <fpage>5018</fpage>
               <lpage>5022</lpage>
            </element-citation>
         </ref>
         <ref id="ref3">
            <element-citation publication-type="journal" id="cit3">
               <name name-style="western">
                  <surname>Choudhary</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kumar</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gnad</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nielsen</surname>
                  <given-names>M. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rehman</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Walther</surname>
                  <given-names>T. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Olsen</surname>
                  <given-names>J. V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mann</surname>
                  <given-names>M.</given-names>
               </name>
               <article-title>Lysine acetylation
targets protein complexes and co-regulates major cellular functions</article-title>
               <source>Science</source>
               <year>2009</year>
               <volume>325</volume>
               <fpage>834</fpage>
               <lpage>840</lpage>
            </element-citation>
         </ref>
         <ref id="ref4">
            <element-citation publication-type="journal" id="cit4">
               <name name-style="western">
                  <surname>Brownell</surname>
                  <given-names>J. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhou</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ranalli</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kobayashi</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Edmondson</surname>
                  <given-names>D. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Roth</surname>
                  <given-names>S. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Allis</surname>
                  <given-names>C. D.</given-names>
               </name>
               <article-title>Tetrahymena histone
acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation
to gene activation</article-title>
               <source>Cell</source>
               <year>1996</year>
               <volume>84</volume>
               <fpage>843</fpage>
               <lpage>851</lpage>
            </element-citation>
         </ref>
         <ref id="ref5">
            <element-citation publication-type="journal" id="cit5">
               <name name-style="western">
                  <surname>Taunton</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hassig</surname>
                  <given-names>C. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schreiber</surname>
                  <given-names>S. L.</given-names>
               </name>
               <article-title>A mammalian
histone deacetylase related
to the yeast transcriptional regulator Rpd3p</article-title>
               <source>Science</source>
               <year>1996</year>
               <volume>272</volume>
               <fpage>408</fpage>
               <lpage>411</lpage>
            </element-citation>
         </ref>
         <ref id="ref6">
            <element-citation publication-type="journal" id="cit6">
               <name name-style="western">
                  <surname>Dhalluin</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Carlson</surname>
                  <given-names>J. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zeng</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>He</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Aggarwal</surname>
                  <given-names>A. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhou</surname>
                  <given-names>M.-M.</given-names>
               </name>
               <article-title>Structure and ligand of a histone
acetyltransferase
bromodomain</article-title>
               <source>Nature</source>
               <year>1999</year>
               <volume>399</volume>
               <fpage>491</fpage>
               <lpage>496</lpage>
            </element-citation>
         </ref>
         <ref id="ref7">
            <element-citation publication-type="journal" id="cit7">
               <name name-style="western">
                  <surname>Winston</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Allis</surname>
                  <given-names>C. D.</given-names>
               </name>
               <article-title>The bromodomain: a chromatin-targeting
module?</article-title>
               <source>Nat. Struct. Biol.</source>
               <year>1999</year>
               <volume>6</volume>
               <fpage>601</fpage>
               <lpage>604</lpage>
            </element-citation>
         </ref>
         <ref id="ref8">
            <element-citation publication-type="journal" id="cit8">
               <name name-style="western">
                  <surname>Mujtaba</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>He</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zeng</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yan</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Plotnikova</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sachchidanand</surname>
               </name>
               <name name-style="western">
                  <surname>Sanchez</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zeleznik-Le</surname>
                  <given-names>N. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ronai</surname>
                  <given-names>Z.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhou</surname>
                  <given-names>M.-M.</given-names>
               </name>
               <article-title>Structural
mechanism of the bromodomain of the coactivator CBP in p53 transcriptional
activation</article-title>
               <source>Mol. Cell</source>
               <year>2004</year>
               <volume>13</volume>
               <fpage>251</fpage>
               <lpage>263</lpage>
            </element-citation>
         </ref>
         <ref id="ref9">
            <element-citation publication-type="journal" id="cit9">
               <name name-style="western">
                  <surname>Kouzarides</surname>
                  <given-names>T.</given-names>
               </name>
               <article-title>Acetylation:
a regulatory modification to rival phosphorylation ?</article-title>
               <source>EMBO J.</source>
               <year>2000</year>
               <volume>19</volume>
               <fpage>1176</fpage>
               <lpage>1179</lpage>
            </element-citation>
         </ref>
         <ref id="ref10">
            <element-citation publication-type="journal" id="cit10">
               <name name-style="western">
                  <surname>Choudhary</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Weinert</surname>
                  <given-names>B. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nishida</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Verdin</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mann</surname>
                  <given-names>M.</given-names>
               </name>
               <article-title>The growing
landscape of lysine acetylation links metabolism and cell signalling</article-title>
               <source>Nat. Rev. Mol. Cell Biol.</source>
               <year>2014</year>
               <volume>15</volume>
               <fpage>536</fpage>
               <lpage>550</lpage>
            </element-citation>
         </ref>
         <ref id="ref11">
            <element-citation publication-type="journal" id="cit11">
               <name name-style="western">
                  <surname>Strahl</surname>
                  <given-names>B. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Allis</surname>
                  <given-names>C. D.</given-names>
               </name>
               <article-title>The language of covalent histone modifications</article-title>
               <source>Nature</source>
               <year>2000</year>
               <volume>403</volume>
               <fpage>41</fpage>
               <lpage>45</lpage>
            </element-citation>
         </ref>
         <ref id="ref12">
            <element-citation publication-type="journal" id="cit12">
               <name name-style="western">
                  <surname>Gardner</surname>
                  <given-names>K. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Allis</surname>
                  <given-names>C. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Strahl</surname>
                  <given-names>B. D.</given-names>
               </name>
               <article-title>Operating on chromatin, a colorful
language where context matters</article-title>
               <source>J. Mol. Biol.</source>
               <year>2011</year>
               <volume>409</volume>
               <fpage>36</fpage>
               <lpage>46</lpage>
            </element-citation>
         </ref>
         <ref id="ref13">
            <element-citation publication-type="journal" id="cit13">
               <name name-style="western">
                  <surname>Filippakopoulos</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Knapp</surname>
                  <given-names>S.</given-names>
               </name>
               <article-title>Targeting bromodomains:
epigenetic readers of lysine acetylation</article-title>
               <source>Nat.
Rev. Drug Discovery</source>
               <year>2014</year>
               <volume>13</volume>
               <fpage>337</fpage>
               <lpage>356</lpage>
            </element-citation>
         </ref>
         <ref id="ref14">
            <element-citation publication-type="journal" id="cit14">
               <name name-style="western">
                  <surname>Filippakopoulos</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Picaud</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mangos</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Keates</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lambert</surname>
                  <given-names>J.-P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Barsyte-Lovejoy</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Felletar</surname>
                  <given-names>I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Volkmer</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Müller</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pawson</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gingras</surname>
                  <given-names>A.-C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Arrowsmith</surname>
                  <given-names>C. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Knapp</surname>
                  <given-names>S.</given-names>
               </name>
               <article-title>Histone recognition and large-scale structural analysis of the human
bromodomain family</article-title>
               <source>Cell</source>
               <year>2012</year>
               <volume>149</volume>
               <fpage>214</fpage>
               <lpage>231</lpage>
            </element-citation>
         </ref>
         <ref id="ref15">
            <element-citation publication-type="journal" id="cit15">
               <name name-style="western">
                  <surname>Wilson</surname>
                  <given-names>A. J.</given-names>
               </name>
               <article-title>Inhibition
of protein-protein interactions using designed molecules</article-title>
               <source>Chem. Soc. Rev.</source>
               <year>2009</year>
               <volume>38</volume>
               <fpage>3289</fpage>
               <lpage>3300</lpage>
            </element-citation>
         </ref>
         <ref id="ref16">
            <element-citation publication-type="journal" id="cit16">
               <name name-style="western">
                  <surname>Hewings</surname>
                  <given-names>D. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rooney</surname>
                  <given-names>T. P. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jennings</surname>
                  <given-names>L. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hay</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schofield</surname>
                  <given-names>C. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brennan</surname>
                  <given-names>P. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Knapp</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Conway</surname>
                  <given-names>S. J.</given-names>
               </name>
               <article-title>Progress in the
development and application of small molecule inhibitors of bromodomain-acetyl-lysine
interactions</article-title>
               <source>J. Med. Chem.</source>
               <year>2012</year>
               <volume>55</volume>
               <fpage>9393</fpage>
               <lpage>9413</lpage>
            </element-citation>
         </ref>
         <ref id="ref17">
            <element-citation publication-type="journal" id="cit17">
               <name name-style="western">
                  <surname>Jennings</surname>
                  <given-names>L. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Measures</surname>
                  <given-names>A. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wilson</surname>
                  <given-names>B. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Conway</surname>
                  <given-names>S. J.</given-names>
               </name>
               <article-title>Phenotypic
screening
and fragment-based approaches to the discovery of small-molecule bromodomain
ligands</article-title>
               <source>Future Med. Chem.</source>
               <year>2014</year>
               <volume>6</volume>
               <fpage>179</fpage>
               <lpage>204</lpage>
            </element-citation>
         </ref>
         <ref id="ref18">
            <element-citation publication-type="journal" id="cit18">
               <name name-style="western">
                  <surname>Garnier</surname>
                  <given-names>J.-M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sharp</surname>
                  <given-names>P. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Burns</surname>
                  <given-names>C. J.</given-names>
               </name>
               <article-title>BET bromodomain
inhibitors: a patent
review</article-title>
               <source>Expert Opin. Ther. Pat.</source>
               <year>2014</year>
               <volume>24</volume>
               <fpage>185</fpage>
               <lpage>199</lpage>
            </element-citation>
         </ref>
         <ref id="ref19">
            <element-citation publication-type="journal" id="cit19">
               <name name-style="western">
                  <surname>Gallenkamp</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gelato</surname>
                  <given-names>K. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Haendler</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Weinmann</surname>
                  <given-names>H.</given-names>
               </name>
               <article-title>Bromodomains and their
pharmacological inhibitors</article-title>
               <source>ChemMedChem</source>
               <year>2014</year>
               <volume>9</volume>
               <fpage>438</fpage>
               <lpage>464</lpage>
            </element-citation>
         </ref>
         <ref id="ref20">
            <element-citation publication-type="journal" id="cit20">
               <name name-style="western">
                  <surname>Jang</surname>
                  <given-names>M. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mochizuki</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhou</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jeong</surname>
                  <given-names>H.-S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brady</surname>
                  <given-names>J. N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ozato</surname>
                  <given-names>K.</given-names>
               </name>
               <article-title>The bromodomain
protein Brd4 is a positive regulatory component of
P-TEFb and stimulates RNA polymerase II-dependent transcription</article-title>
               <source>Mol. Cell</source>
               <year>2005</year>
               <volume>19</volume>
               <fpage>523</fpage>
               <lpage>534</lpage>
            </element-citation>
         </ref>
         <ref id="ref21">
            <element-citation publication-type="journal" id="cit21">
               <name name-style="western">
                  <surname>Gaucher</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Boussouar</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Montellier</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Curtet</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Buchou</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bertrand</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hery</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jounier</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Depaux</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Vitte</surname>
                  <given-names>A.-L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Guardiola</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pernet</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Debernardi</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lopez</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Holota</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Imbert</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wolgemuth</surname>
                  <given-names>D. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gérard</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rousseaux</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Khochbin</surname>
                  <given-names>S.</given-names>
               </name>
               <article-title>Bromodomain-dependent
stage-specific male genome programming by Brdt</article-title>
               <source>EMBO J.</source>
               <year>2012</year>
               <volume>31</volume>
               <fpage>3809</fpage>
               <lpage>3820</lpage>
            </element-citation>
         </ref>
         <ref id="ref22">
            <element-citation publication-type="journal" id="cit22">
               <name name-style="western">
                  <surname>Mujtaba</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>He</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zeng</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Farooq</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Carlson</surname>
                  <given-names>J. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ott</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Verdin</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhou</surname>
                  <given-names>M.-M.</given-names>
               </name>
               <article-title>Structural basis of lysine-acetylated
HIV-1 Tat recognition by PCAF bromodomain</article-title>
               <source>Mol.
Cell</source>
               <year>2002</year>
               <volume>9</volume>
               <fpage>575</fpage>
               <lpage>586</lpage>
            </element-citation>
         </ref>
         <ref id="ref23">
            <element-citation publication-type="journal" id="cit23">
               <name name-style="western">
                  <surname>Pan</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mezei</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mujtaba</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Muller</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zeng</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Li</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>Z.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhou</surname>
                  <given-names>M.-M.</given-names>
               </name>
               <article-title>Structure-guided optimization of
small molecules inhibiting human immunodeficiency virus 1 Tat association
with the human coactivator p300/CREB binding protein-associated factor</article-title>
               <source>J. Med. Chem.</source>
               <year>2007</year>
               <volume>50</volume>
               <fpage>2285</fpage>
               <lpage>2288</lpage>
            </element-citation>
         </ref>
         <ref id="ref24">
            <element-citation publication-type="journal" id="cit24">
               <name name-style="western">
                  <surname>Filippakopoulos</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Qi</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Picaud</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shen</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Smith</surname>
                  <given-names>W. B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fedorov</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Morse</surname>
                  <given-names>E. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Keates</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hickman</surname>
                  <given-names>T. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Felletar</surname>
                  <given-names>I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Philpott</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Munro</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>McKeown</surname>
                  <given-names>M. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Christie</surname>
                  <given-names>A. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>West</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cameron</surname>
                  <given-names>M. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schwartz</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Heightman</surname>
                  <given-names>T. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>La Thangue</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>French</surname>
                  <given-names>C. a</given-names>
               </name>
               <name name-style="western">
                  <surname>Wiest</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kung</surname>
                  <given-names>A. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Knapp</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bradner</surname>
                  <given-names>J. E.</given-names>
               </name>
               <article-title>Selective inhibition
of BET bromodomains</article-title>
               <source>Nature</source>
               <year>2010</year>
               <volume>468</volume>
               <fpage>1067</fpage>
               <lpage>1073</lpage>
            </element-citation>
         </ref>
         <ref id="ref25">
            <element-citation publication-type="journal" id="cit25">
               <name name-style="western">
                  <surname>Nicodeme</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jeffrey</surname>
                  <given-names>K. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schaefer</surname>
                  <given-names>U.</given-names>
               </name>
               <name name-style="western">
                  <surname>Beinke</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dewell</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chung</surname>
                  <given-names>C.-W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chandwani</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Marazzi</surname>
                  <given-names>I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wilson</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Coste</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>White</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kirilovsky</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rice</surname>
                  <given-names>C. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lora</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Prinjha</surname>
                  <given-names>R. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tarakhovsky</surname>
                  <given-names>A.</given-names>
               </name>
               <article-title>Suppression of inflammation by a synthetic histone
mimic</article-title>
               <source>Nature</source>
               <year>2010</year>
               <volume>468</volume>
               <fpage>1119</fpage>
               <lpage>1123</lpage>
            </element-citation>
         </ref>
         <ref id="ref26">
            <element-citation publication-type="journal" id="cit26">
               <name name-style="western">
                  <surname>Bunin</surname>
                  <given-names>B. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Plunkett</surname>
                  <given-names>M. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ellman</surname>
                  <given-names>J. A.</given-names>
               </name>
               <article-title>The combinatorial synthesis and chemical
and biological evaluation of a 1,4-benzodiazepine library</article-title>
               <source>Proc. Natl. Acad. Sci. U.S.A.</source>
               <year>1994</year>
               <volume>91</volume>
               <fpage>4708</fpage>
               <lpage>4712</lpage>
            </element-citation>
         </ref>
         <ref id="ref27">
            <element-citation publication-type="journal" id="cit27">
               <name name-style="western">
                  <surname>Wu</surname>
                  <given-names>X.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schultz</surname>
                  <given-names>P. G.</given-names>
               </name>
               <article-title>Synthesis at the interface of chemistry and biology</article-title>
               <source>J. Am. Chem. Soc.</source>
               <year>2009</year>
               <volume>131</volume>
               <fpage>12497</fpage>
               <lpage>12515</lpage>
            </element-citation>
         </ref>
         <ref id="ref28">
            <element-citation publication-type="journal" id="cit28">
               <name name-style="western">
                  <surname>Mirguet</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gosmini</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Toum</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Clement</surname>
                  <given-names>C. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Melanie</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brusq</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mordaunt</surname>
                  <given-names>J. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Grimes</surname>
                  <given-names>R. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Crowe</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pineau</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ajakane</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Daugan</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jeffrey</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cutler</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Haynes</surname>
                  <given-names>A. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Smithers</surname>
                  <given-names>N. N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chung</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bamborough</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Uings</surname>
                  <given-names>I. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lewis</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Witherington</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Parr</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Prinjha</surname>
                  <given-names>R. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nicodeme</surname>
                  <given-names>E.</given-names>
               </name>
               <article-title>Discovery of epigenetic
regulator I-BET762: lead optimization to afford a clinical candidate
inhibitor of the BET bromodomains</article-title>
               <source>J. Med. Chem.</source>
               <year>2013</year>
               <volume>56</volume>
               <fpage>7501</fpage>
               <lpage>7515</lpage>
            </element-citation>
         </ref>
         <ref id="ref29">
            <element-citation publication-type="journal" id="cit29">
               <name name-style="western">
                  <surname>Chung</surname>
                  <given-names>C.-W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Coste</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>White</surname>
                  <given-names>J. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mirguet</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wilde</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gosmini</surname>
                  <given-names>R. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Delves</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Magny</surname>
                  <given-names>S. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Woodward</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hughes</surname>
                  <given-names>S. a</given-names>
               </name>
               <name name-style="western">
                  <surname>Boursier</surname>
                  <given-names>E. V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Flynn</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bouillot</surname>
                  <given-names>A. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bamborough</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brusq</surname>
                  <given-names>J.-M. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gellibert</surname>
                  <given-names>F. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jones</surname>
                  <given-names>E. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Riou</surname>
                  <given-names>A. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Homes</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Martin</surname>
                  <given-names>S. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Uings</surname>
                  <given-names>I. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Toum</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Clement</surname>
                  <given-names>C. a</given-names>
               </name>
               <name name-style="western">
                  <surname>Boullay</surname>
                  <given-names>A.-B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Grimley</surname>
                  <given-names>R. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Blandel</surname>
                  <given-names>F. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Prinjha</surname>
                  <given-names>R. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kirilovsky</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nicodeme</surname>
                  <given-names>E.</given-names>
               </name>
               <article-title>Discovery and characterization of
small molecule inhibitors of the BET family bromodomains</article-title>
               <source>J. Med. Chem.</source>
               <year>2011</year>
               <volume>54</volume>
               <fpage>3827</fpage>
               <lpage>3838</lpage>
            </element-citation>
         </ref>
         <ref id="ref30">
            <mixed-citation publication-type="patent" id="cit30"><person-group person-group-type="allauthors"><name name-style="western"><surname>Chiba</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Manabe</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Moriwaki</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Nakagawa</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Shindo</surname><given-names>M.</given-names></name>, and <name name-style="western"><surname>Tahara</surname><given-names>T.</given-names></name></person-group> (<year>1996</year>) <article-title>Therapeutic agent for osteoporosis and diazepine compound</article-title>. <patent>US5753649A</patent>.</mixed-citation>
         </ref>
         <ref id="ref31">
            <mixed-citation publication-type="patent" id="cit31"><person-group person-group-type="allauthors"><name name-style="western"><surname>Miyoshi</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Ooike</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Iwata</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Hikwa</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Sugahara</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Hikwawa</surname><given-names>H.</given-names></name>, and <name name-style="western"><surname>Sugahara</surname><given-names>K.</given-names></name></person-group> (<year>2009</year>) <article-title>Antitumor agent</article-title>. <patent>WO2009084693</patent>.</mixed-citation>
         </ref>
         <ref id="ref32">
            <mixed-citation publication-type="patent" id="cit32"><person-group person-group-type="allauthors"><name name-style="western"><surname>Adachi</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Hikwawa</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Hamada</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Endoh</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Ishibuchi</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Fujie</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Tanaka</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Sugahara</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Kouichi</surname><given-names>O.</given-names></name>, and <name name-style="western"><surname>Murata</surname><given-names>M.</given-names></name></person-group> (<year>2006</year>) <article-title>Thienotriazolodiazepine
compound and a medicinal use thereof</article-title>. <patent>WO2006129623</patent>.</mixed-citation>
         </ref>
         <ref id="ref33">
            <element-citation publication-type="journal" id="cit33">
               <name name-style="western">
                  <surname>Noel</surname>
                  <given-names>J. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Iwata</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ooike</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sugahara</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nakamura</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Daibata</surname>
                  <given-names>M.</given-names>
               </name>
               <source>Mol. Cancer Ther.</source>
               <year>2013</year>
               <volume>12</volume>
               <issue>11 Suppl</issue>
               <fpage>C244</fpage>
            </element-citation>
         </ref>
         <ref id="ref34">
            <mixed-citation publication-type="patent" id="cit34"><person-group person-group-type="allauthors"><name name-style="western"><surname>Schmees</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Kuhnke</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Haendler</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Neuhaus</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Lejeune</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Siegel</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Krüger</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Ernesto</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Künzer</surname><given-names>H.</given-names></name>, and <name name-style="western"><surname>Gallenkamp</surname><given-names>D.</given-names></name></person-group> (<year>2014</year>) <article-title>Bet protein-inhibiting 5-aryl
triazole azepines</article-title>. <patent>WO2014048945</patent>.</mixed-citation>
         </ref>
         <ref id="ref35">
            <element-citation publication-type="journal" id="cit35">
               <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Liu</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhong</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Plotnikov</surname>
                  <given-names>A. N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zeng</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rusinova</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gerona-Nevarro</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Moshkina</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Joshua</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chuang</surname>
                  <given-names>P. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ohlmeyer</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>He</surname>
                  <given-names>J. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhou</surname>
                  <given-names>M.-M.</given-names>
               </name>
               <article-title>Down-regulation
of NF-κB transcriptional activity in HIV-associated kidney disease
by BRD4 inhibition</article-title>
               <source>J. Biol. Chem.</source>
               <year>2012</year>
               <volume>287</volume>
               <fpage>28840</fpage>
               <lpage>28851</lpage>
            </element-citation>
         </ref>
         <ref id="ref36">
            <mixed-citation publication-type="patent" id="cit36"><person-group person-group-type="allauthors"><name name-style="western"><surname>Arnold</surname><given-names>L. D.</given-names></name>, <name name-style="western"><surname>Foreman</surname><given-names>K. W.</given-names></name>, and <name name-style="western"><surname>Werner</surname><given-names>D. S.</given-names></name></person-group> (<year>2013</year>) <article-title>Bromodomain ligands capable of
dimerizing in an aqueous solution,
and methods of using same</article-title>. <patent>WO2013033270</patent>.</mixed-citation>
         </ref>
         <ref id="ref37">
            <element-citation publication-type="journal" id="cit37">
               <name name-style="western">
                  <surname>Hewings</surname>
                  <given-names>D. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Philpott</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fedorov</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Uttarkar</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Filippakopoulos</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Picaud</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Vuppusetty</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Marsden</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Knapp</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Conway</surname>
                  <given-names>S. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Heightman</surname>
                  <given-names>T. D.</given-names>
               </name>
               <article-title>3,5-Dimethylisoxazoles
act as acetyl-lysine-mimetic bromodomain ligands</article-title>
               <source>J. Med. Chem.</source>
               <year>2011</year>
               <volume>54</volume>
               <fpage>6761</fpage>
               <lpage>6770</lpage>
            </element-citation>
         </ref>
         <ref id="ref38">
            <element-citation publication-type="journal" id="cit38">
               <name name-style="western">
                  <surname>Dawson</surname>
                  <given-names>M. a</given-names>
               </name>
               <name name-style="western">
                  <surname>Prinjha</surname>
                  <given-names>R. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dittmann</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Giotopoulos</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bantscheff</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chan</surname>
                  <given-names>W.-I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Robson</surname>
                  <given-names>S. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chung</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hopf</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Savitski</surname>
                  <given-names>M. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Huthmacher</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gudgin</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lugo</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Beinke</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chapman</surname>
                  <given-names>T. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Roberts</surname>
                  <given-names>E. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Soden</surname>
                  <given-names>P. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Auger</surname>
                  <given-names>K. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mirguet</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Doehner</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Delwel</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Burnett</surname>
                  <given-names>A. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jeffrey</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Drewes</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Huntly</surname>
                  <given-names>B. J. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kouzarides</surname>
                  <given-names>T.</given-names>
               </name>
               <article-title>Inhibition
of BET recruitment to chromatin as an effective treatment for MLL-fusion
leukaemia</article-title>
               <source>Nature</source>
               <year>2011</year>
               <volume>478</volume>
               <fpage>529</fpage>
               <lpage>533</lpage>
            </element-citation>
         </ref>
         <ref id="ref39">
            <element-citation publication-type="journal" id="cit39">
               <name name-style="western">
                  <surname>Bamborough</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Diallo</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Goodacre</surname>
                  <given-names>J. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gordon</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lewis</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Seal</surname>
                  <given-names>J. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wilson</surname>
                  <given-names>D. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Woodrow</surname>
                  <given-names>M. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chung</surname>
                  <given-names>C.</given-names>
               </name>
               <article-title>Fragment-based
discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole
sulfonamides</article-title>
               <source>J. Med. Chem.</source>
               <year>2012</year>
               <volume>55</volume>
               <fpage>587</fpage>
               <lpage>596</lpage>
            </element-citation>
         </ref>
         <ref id="ref40">
            <element-citation publication-type="journal" id="cit40">
               <name name-style="western">
                  <surname>Mirguet</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lamotte</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Donche</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Toum</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gellibert</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bouillot</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gosmini</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nguyen</surname>
                  <given-names>V.-L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Delannée</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Seal</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Blandel</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Boullay</surname>
                  <given-names>A.-B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Boursier</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Martin</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brusq</surname>
                  <given-names>J.-M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Krysa</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Riou</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tellier</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Costaz</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Huet</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dudit</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Trottet</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kirilovsky</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nicodeme</surname>
                  <given-names>E.</given-names>
               </name>
               <article-title>From ApoA1 upregulation
to BET family bromodomain inhibition: discovery of I-BET151</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2012</year>
               <volume>22</volume>
               <fpage>2963</fpage>
               <lpage>2967</lpage>
            </element-citation>
         </ref>
         <ref id="ref41">
            <element-citation publication-type="journal" id="cit41">
               <name name-style="western">
                  <surname>Seal</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lamotte</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Donche</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bouillot</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mirguet</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gellibert</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nicodeme</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Krysa</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kirilovsky</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Beinke</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>McCleary</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rioja</surname>
                  <given-names>I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bamborough</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chung</surname>
                  <given-names>C.-W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gordon</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lewis</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Walker</surname>
                  <given-names>A. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cutler</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lugo</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wilson</surname>
                  <given-names>D. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Witherington</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Prinjha</surname>
                  <given-names>R. K.</given-names>
               </name>
               <article-title>Identification of a novel series of BET family bromodomain
inhibitors: binding mode and profile of I-BET151 (GSK1210151A)</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2012</year>
               <volume>22</volume>
               <fpage>2968</fpage>
               <lpage>2972</lpage>
            </element-citation>
         </ref>
         <ref id="ref42">
            <element-citation publication-type="journal" id="cit42">
               <name name-style="western">
                  <surname>Hewings</surname>
                  <given-names>D. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fedorov</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Filippakopoulos</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Martin</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Picaud</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tumber</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wells</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Olcina</surname>
                  <given-names>M. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Freeman</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gill</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ritchie</surname>
                  <given-names>A. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sheppard</surname>
                  <given-names>D. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Russell</surname>
                  <given-names>A. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hammond</surname>
                  <given-names>E. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Knapp</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brennan</surname>
                  <given-names>P. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Conway</surname>
                  <given-names>S. J.</given-names>
               </name>
               <article-title>Optimization
of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands</article-title>
               <source>J. Med. Chem.</source>
               <year>2013</year>
               <volume>56</volume>
               <fpage>3217</fpage>
               <lpage>3227</lpage>
            </element-citation>
         </ref>
         <ref id="ref43">
            <element-citation publication-type="journal" id="cit43">
               <name name-style="western">
                  <surname>Gehling</surname>
                  <given-names>V. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hewitt</surname>
                  <given-names>M. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Vaswani</surname>
                  <given-names>R. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Leblanc</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Co</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nasveschuk</surname>
                  <given-names>C. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Taylor</surname>
                  <given-names>A. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Harmange</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Audia</surname>
                  <given-names>J. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pardo</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Joshi</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sandy</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mertz</surname>
                  <given-names>J. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sims</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bergeron</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bryant</surname>
                  <given-names>B. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bellon</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Poy</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jayaram</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sankaranarayanan</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yellapantula</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Srinivasamurthy</surname>
                  <given-names>N. B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Birudukota</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Albrecht</surname>
                  <given-names>B. K.</given-names>
               </name>
               <article-title>Discovery, design,
and optimization of isoxazole azepine BET inhibitors</article-title>
               <source>ACS Med. Chem. Lett.</source>
               <year>2013</year>
               <volume>4</volume>
               <fpage>835</fpage>
               <lpage>840</lpage>
            </element-citation>
         </ref>
         <ref id="ref44">
            <element-citation publication-type="journal" id="cit44">
               <name name-style="western">
                  <surname>Hay</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fedorov</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Filippakopoulos</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Martin</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Philpott</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Picaud</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hewings</surname>
                  <given-names>D. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Uttakar</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Heightman</surname>
                  <given-names>T. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Conway</surname>
                  <given-names>S. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Knapp</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brennan</surname>
                  <given-names>P. E.</given-names>
               </name>
               <article-title>The design and synthesis
of 5-and 6-isoxazolylbenzimidazoles as selective inhibitors of the
BET bromodomains</article-title>
               <source>MedChemComm</source>
               <year>2013</year>
               <volume>4</volume>
               <fpage>140</fpage>
               <lpage>144</lpage>
            </element-citation>
         </ref>
         <ref id="ref45">
            <element-citation publication-type="journal" id="cit45">
               <name name-style="western">
                  <surname>Hay</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fedorov</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Martin</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Singleton</surname>
                  <given-names>D. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tallant</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wells</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Picaud</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Philpott</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Monteiro</surname>
                  <given-names>O. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rogers</surname>
                  <given-names>C. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Conway</surname>
                  <given-names>S. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rooney</surname>
                  <given-names>T. P. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tumber</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yapp</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Filippakopoulos</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bunnage</surname>
                  <given-names>M. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Müller</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Knapp</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schofield</surname>
                  <given-names>C. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brennan</surname>
                  <given-names>P. E.</given-names>
               </name>
               <article-title>Discovery and optimization of small-molecule ligands
for the CBP/p300 bromodomains</article-title>
               <source>J. Am. Chem.
Soc.</source>
               <year>2014</year>
               <volume>136</volume>
               <fpage>9308</fpage>
               <lpage>9319</lpage>
            </element-citation>
         </ref>
         <ref id="ref46">
            <element-citation publication-type="journal" id="cit46">
               <name name-style="western">
                  <surname>Sharp</surname>
                  <given-names>P. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Garnier</surname>
                  <given-names>J.-M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Huang</surname>
                  <given-names>D. C. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Burns</surname>
                  <given-names>C. J.</given-names>
               </name>
               <article-title>Evaluation of functional
groups as acetyl-lysine mimetics for BET bromodomain inhibition</article-title>
               <source>Med. Chem. Commun.</source>
               <year>2014</year>
               <volume>5</volume>
               <fpage>1834</fpage>
               <lpage>1842</lpage>
            </element-citation>
         </ref>
         <ref id="ref47">
            <element-citation publication-type="journal" id="cit47">
               <name name-style="western">
                  <surname>Picaud</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wells</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Felletar</surname>
                  <given-names>I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brotherton</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Martin</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Savitsky</surname>
                  <given-names>P.</given-names>
               </name>
               <article-title>RVX-208, an inhibitor of BET transcriptional
regulators with selectivity for the second bromodomain</article-title>
               <source>Proc. Natl. Acad. Sci. U.S.A.</source>
               <year>2013</year>
               <volume>110</volume>
               <fpage>19754</fpage>
               <lpage>19759</lpage>
            </element-citation>
         </ref>
         <ref id="ref48">
            <element-citation publication-type="journal" id="cit48">
               <name name-style="western">
                  <surname>McLure</surname>
                  <given-names>K. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gesner</surname>
                  <given-names>E. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tsujikawa</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kharenko</surname>
                  <given-names>O. a</given-names>
               </name>
               <name name-style="western">
                  <surname>Attwell</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Campeau</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wasiak</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Stein</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>White</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fontano</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Suto</surname>
                  <given-names>R. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wong</surname>
                  <given-names>N. C. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wagner</surname>
                  <given-names>G. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hansen</surname>
                  <given-names>H. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Young</surname>
                  <given-names>P. R.</given-names>
               </name>
               <article-title>RVX-208, an inducer of ApoA-I in
humans, is a BET bromodomain antagonist</article-title>
               <source>PLoS
One</source>
               <year>2013</year>
               <volume>8</volume>
               <fpage>e83190</fpage>
            </element-citation>
         </ref>
         <ref id="ref49">
            <element-citation publication-type="journal" id="cit49">
               <name name-style="western">
                  <surname>Bailey</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jahagirdar</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gordon</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hafiane</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Campbell</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chatur</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wagner</surname>
                  <given-names>G. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hansen</surname>
                  <given-names>H. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chiacchia</surname>
                  <given-names>F. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Johansson</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Krimbou</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wong</surname>
                  <given-names>N. C. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Genest</surname>
                  <given-names>J.</given-names>
               </name>
               <article-title>RVX-208: a
small molecule that increases apolipoprotein A-1 and high-density
lipoprotein cholesterol in vitro and in vivo</article-title>
               <source>J. Am. Coll. Cardiol.</source>
               <year>2010</year>
               <volume>55</volume>
               <fpage>2580</fpage>
               <lpage>2589</lpage>
            </element-citation>
         </ref>
         <ref id="ref50">
            <element-citation publication-type="journal" id="cit50">
               <name name-style="western">
                  <surname>Nicholls</surname>
                  <given-names>S. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gordon</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Johansson</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wolski</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ballantyne</surname>
                  <given-names>C. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kastelein</surname>
                  <given-names>J. J. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Taylor</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Borgman</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nissen</surname>
                  <given-names>S. E.</given-names>
               </name>
               <article-title>Efficacy
and safety of a novel oral inducer of apolipoprotein a-I synthesis
in statin-treated patients with stable coronary artery disease a randomized
controlled trial</article-title>
               <source>J. Am. Coll. Cardiol.</source>
               <year>2011</year>
               <volume>57</volume>
               <fpage>1111</fpage>
               <lpage>9</lpage>
            </element-citation>
         </ref>
         <ref id="ref51">
            <element-citation publication-type="journal" id="cit51">
               <name name-style="western">
                  <surname>Chung</surname>
                  <given-names>C.-W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dean</surname>
                  <given-names>A. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Woolven</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bamborough</surname>
                  <given-names>P.</given-names>
               </name>
               <article-title>Fragment-based
discovery of bromodomain inhibitors part 1: inhibitor binding modes
and implications for lead discovery</article-title>
               <source>J. Med.
Chem.</source>
               <year>2012</year>
               <volume>55</volume>
               <fpage>576</fpage>
               <lpage>586</lpage>
            </element-citation>
         </ref>
         <ref id="ref52">
            <element-citation publication-type="journal" id="cit52">
               <name name-style="western">
                  <surname>Philpott</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tumber</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fedorov</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Uttarkar</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Filippakopoulos</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Picaud</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Keates</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Felletar</surname>
                  <given-names>I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ciulli</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Knapp</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Heightman</surname>
                  <given-names>T. D.</given-names>
               </name>
               <article-title>Bromodomain-peptide
displacement assays for interactome mapping and inhibitor discovery</article-title>
               <source>Mol. Biosyst.</source>
               <year>2011</year>
               <volume>7</volume>
               <fpage>2899</fpage>
               <lpage>2908</lpage>
            </element-citation>
         </ref>
         <ref id="ref53">
            <element-citation publication-type="journal" id="cit53">
               <name name-style="western">
                  <surname>Fish</surname>
                  <given-names>P. V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Filippakopoulos</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bish</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brennan</surname>
                  <given-names>P. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bunnage</surname>
                  <given-names>M. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cook</surname>
                  <given-names>A. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Federov</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gerstenberger</surname>
                  <given-names>B. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jones</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Knapp</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Marsden</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nocka</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Owen</surname>
                  <given-names>D. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Philpott</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Picaud</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Primiano</surname>
                  <given-names>M. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ralph</surname>
                  <given-names>M. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sciammetta</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Trzupek</surname>
                  <given-names>J. D.</given-names>
               </name>
               <article-title>Identification of
a chemical probe for bromo and extra C-terminal bromodomain inhibition
through optimization of a fragment- derived hit</article-title>
               <source>J. Med. Chem.</source>
               <year>2012</year>
               <volume>55</volume>
               <fpage>9831</fpage>
               <lpage>9837</lpage>
            </element-citation>
         </ref>
         <ref id="ref54">
            <element-citation publication-type="journal" id="cit54">
               <name name-style="western">
                  <surname>Picaud</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Da Costa</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Thanasopoulou</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Filippakopoulos</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fish</surname>
                  <given-names>P. V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Philpott</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fedorov</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brennan</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bunnage</surname>
                  <given-names>M. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Owen</surname>
                  <given-names>D. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bradner</surname>
                  <given-names>J. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Taniere</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>O’Sullivan</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Muller</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schwaller</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Stankovic</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Knapp</surname>
                  <given-names>S.</given-names>
               </name>
               <article-title>PFI-1, a highly selective protein
interaction inhibitor, targeting BET bromodomains</article-title>
               <source>Cancer Res.</source>
               <year>2013</year>
               <volume>73</volume>
               <fpage>3336</fpage>
               <lpage>3346</lpage>
            </element-citation>
         </ref>
         <ref id="ref55">
            <element-citation publication-type="journal" id="cit55">
               <name name-style="western">
                  <surname>Zhao</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cao</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Miao</surname>
                  <given-names>Z.</given-names>
               </name>
               <name name-style="western">
                  <surname>Xu</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>He</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shen</surname>
                  <given-names>J.</given-names>
               </name>
               <article-title>Fragment-based drug discovery of 2-thiazolidinones
as inhibitors of the histone reader BRD4 bromodomain</article-title>
               <source>J. Med. Chem.</source>
               <year>2013</year>
               <volume>56</volume>
               <fpage>3833</fpage>
               <lpage>3851</lpage>
            </element-citation>
         </ref>
         <ref id="ref56">
            <element-citation publication-type="journal" id="cit56">
               <name name-style="western">
                  <surname>Borah</surname>
                  <given-names>J. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mujtaba</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Karakikes</surname>
                  <given-names>I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zeng</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Muller</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Patel</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Moshkina</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Morohashi</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gerona-Navarro</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hajjar</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhou</surname>
                  <given-names>M.-M.</given-names>
               </name>
               <article-title>A small
molecule binding to the coactivator CREB-binding protein blocks apoptosis
in cardiomyocytes</article-title>
               <source>Chem. Biol.</source>
               <year>2011</year>
               <volume>18</volume>
               <fpage>531</fpage>
               <lpage>541</lpage>
            </element-citation>
         </ref>
         <ref id="ref57">
            <element-citation publication-type="journal" id="cit57">
               <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Plotnikov</surname>
                  <given-names>A. N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rusinova</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shen</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Morohashi</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Joshua</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zeng</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mujtaba</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ohlmeyer</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhou</surname>
                  <given-names>M.-M.</given-names>
               </name>
               <article-title>Structure-guided design of potent diazobenzene inhibitors
for the BET bromodomains</article-title>
               <source>J. Med. Chem.</source>
               <year>2013</year>
               <volume>56</volume>
               <fpage>9251</fpage>
               <lpage>9264</lpage>
            </element-citation>
         </ref>
         <ref id="ref58">
            <mixed-citation publication-type="patent" id="cit58"><person-group person-group-type="allauthors"><name name-style="western"><surname>Zhou</surname><given-names>M. M.</given-names></name>, <name name-style="western"><surname>Ohlmeyer</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Mujtaba</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Plotnikov</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Kastrinsky</surname><given-names>D.</given-names></name>, and <name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name></person-group> (<year>2012</year>) <article-title>Inhibitors of bromodomains as modulators
of gene expression</article-title>. <patent>WO2012116170</patent>.</mixed-citation>
         </ref>
         <ref id="ref59">
            <element-citation publication-type="journal" id="cit59">
               <name name-style="western">
                  <surname>Lucas</surname>
                  <given-names>X.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wohlwend</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hügle</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schmidtkunz</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gerhardt</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schüle</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jung</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Einsle</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Günther</surname>
                  <given-names>S.</given-names>
               </name>
               <article-title>4-Acyl pyrroles: mimicking acetylated lysines in histone
code reading</article-title>
               <source>Angew. Chem., Int. Ed.</source>
               <year>2013</year>
               <volume>52</volume>
               <fpage>14055</fpage>
               <lpage>14059</lpage>
            </element-citation>
         </ref>
         <ref id="ref60">
            <mixed-citation publication-type="patent" id="cit60"><person-group person-group-type="allauthors"><name name-style="western"><surname>Demont</surname><given-names>H. E.</given-names></name>, and <name name-style="western"><surname>Gosmini</surname><given-names>R. L. M.</given-names></name></person-group> (<year>2011</year>) <article-title>Thetrahydroquinolines derivatives
as bromodomain inhibitors</article-title>. <patent>WO2011054848</patent>.</mixed-citation>
         </ref>
         <ref id="ref61">
            <element-citation publication-type="journal" id="cit61">
               <name name-style="western">
                  <surname>Wyce</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ganji</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Smitheman</surname>
                  <given-names>K. N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chung</surname>
                  <given-names>C.-W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Korenchuk</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bai</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Barbash</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Le</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Craggs</surname>
                  <given-names>P. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>McCabe</surname>
                  <given-names>M. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kennedy-Wilson</surname>
                  <given-names>K. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sanchez</surname>
                  <given-names>L. V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gosmini</surname>
                  <given-names>R. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Parr</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>McHugh</surname>
                  <given-names>C. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dhanak</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Prinjha</surname>
                  <given-names>R. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Auger</surname>
                  <given-names>K. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tummino</surname>
                  <given-names>P. J.</given-names>
               </name>
               <article-title>BET inhibition silences expression of MYCN and BCL2
and induces cytotoxicity in neuroblastoma tumor models</article-title>
               <source>PLoS One</source>
               <year>2013</year>
               <volume>8</volume>
               <fpage>e72967</fpage>
            </element-citation>
         </ref>
         <ref id="ref62">
            <element-citation publication-type="journal" id="cit62">
               <name name-style="western">
                  <surname>Gosmini</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nguyen</surname>
                  <given-names>V. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Toum</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Simon</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brusq</surname>
                  <given-names>J. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Krysa</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mirguet</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Riou-eymard</surname>
                  <given-names>A. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Boursier</surname>
                  <given-names>E. V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Trottet</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bamborough</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Clark</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chung</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cutler</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Demont</surname>
                  <given-names>E. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kaur</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lewis</surname>
                  <given-names>A. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schilling</surname>
                  <given-names>M. B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Soden</surname>
                  <given-names>P. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Taylor</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Walker</surname>
                  <given-names>A. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Walker</surname>
                  <given-names>M. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Prinjha</surname>
                  <given-names>R. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nicodeme</surname>
                  <given-names>E.</given-names>
               </name>
               <article-title>The discovery of I-BET726 (GSK1324726A),
a potent tetrahydroquinoline ApoA1 up-regulator and selective BET
bromodomain inhibitor</article-title>
               <source>J. Med. Chem.</source>
               <year>2014</year>
               <volume>57</volume>
               <fpage>8111</fpage>
               <lpage>8131</lpage>
            </element-citation>
         </ref>
         <ref id="ref63">
            <element-citation publication-type="journal" id="cit63">
               <name name-style="western">
                  <surname>Martin</surname>
                  <given-names>M. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Olesen</surname>
                  <given-names>S. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Georg</surname>
                  <given-names>G. I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schönbrunn</surname>
                  <given-names>E.</given-names>
               </name>
               <article-title>Cyclin-dependent
kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition
site of bromodomains</article-title>
               <source>ACS Chem. Biol.</source>
               <year>2013</year>
               <volume>8</volume>
               <fpage>2360</fpage>
               <lpage>2365</lpage>
            </element-citation>
         </ref>
         <ref id="ref64">
            <element-citation publication-type="journal" id="cit64">
               <name name-style="western">
                  <surname>Dittmann</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Werner</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chung</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Savitski</surname>
                  <given-names>M. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fa</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Grandi</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hopf</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lindon</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Neubauer</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Prinjha</surname>
                  <given-names>R. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bantsche</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Drewes</surname>
                  <given-names>G.</given-names>
               </name>
               <article-title>The commonly used PI3-kinase
probe LY294002 is an inhibitor of BET bromodomains</article-title>
               <source>ACS Chem. Biol.</source>
               <year>2014</year>
               <volume>9</volume>
               <fpage>495</fpage>
               <lpage>502</lpage>
            </element-citation>
         </ref>
         <ref id="ref65">
            <element-citation publication-type="journal" id="cit65">
               <name name-style="western">
                  <surname>Devaiah</surname>
                  <given-names>B. N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lewis</surname>
                  <given-names>B. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cherman</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hewitt</surname>
                  <given-names>M. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Albrecht</surname>
                  <given-names>B. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Robey</surname>
                  <given-names>P. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ozato</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sims</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Singer</surname>
                  <given-names>D. S.</given-names>
               </name>
               <article-title>BRD4 is
an atypical kinase that phosphorylates serine 2 of the RNA polymerase
II carboxy-terminal domain</article-title>
               <source>Proc. Natl. Acad.
Sci. U.S.A.</source>
               <year>2012</year>
               <volume>109</volume>
               <fpage>6927</fpage>
               <lpage>6932</lpage>
            </element-citation>
         </ref>
         <ref id="ref66">
            <element-citation publication-type="journal" id="cit66">
               <name name-style="western">
                  <surname>Gharbi</surname>
                  <given-names>S.
I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zvelebil</surname>
                  <given-names>M. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shuttleworth</surname>
                  <given-names>S. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hancox</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Saghir</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Timms</surname>
                  <given-names>J. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Waterfield</surname>
                  <given-names>M. D.</given-names>
               </name>
               <article-title>Exploring the specificity of the
PI3K family inhibitor LY294002</article-title>
               <source>Biochem. J.</source>
               <year>2007</year>
               <volume>404</volume>
               <fpage>15</fpage>
               <lpage>21</lpage>
            </element-citation>
         </ref>
         <ref id="ref67">
            <element-citation publication-type="journal" id="cit67">
               <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>Y. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Choi</surname>
                  <given-names>K.-H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>J.-W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kwon</surname>
                  <given-names>T. K.</given-names>
               </name>
               <article-title>LY294002 inhibits
LPS-induced NO production through a inhibition of NF-kappaB activation:
independent mechanism of phosphatidylinositol 3-kinase</article-title>
               <source>Immunol. Lett.</source>
               <year>2005</year>
               <volume>99</volume>
               <fpage>45</fpage>
               <lpage>50</lpage>
            </element-citation>
         </ref>
         <ref id="ref68">
            <element-citation publication-type="journal" id="cit68">
               <name name-style="western">
                  <surname>Huang</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>X.-D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhou</surname>
                  <given-names>M.-M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ozato</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>L.-F.</given-names>
               </name>
               <article-title>Brd4 coactivates
transcriptional activation of NF-kappaB via specific binding to acetylated
RelA</article-title>
               <source>Mol. Cell. Biol.</source>
               <year>2009</year>
               <volume>29</volume>
               <fpage>1375</fpage>
               <lpage>87</lpage>
            </element-citation>
         </ref>
         <ref id="ref69">
            <element-citation publication-type="journal" id="cit69">
               <name name-style="western">
                  <surname>Zou</surname>
                  <given-names>Z.</given-names>
               </name>
               <name name-style="western">
                  <surname>Huang</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wu</surname>
                  <given-names>X.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Qi</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bradner</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nair</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>L.-F.</given-names>
               </name>
               <article-title>Brd4 maintains constitutively
active NF-κB in cancer cells by binding to acetylated RelA</article-title>
               <source>Oncogene</source>
               <year>2014</year>
               <volume>33</volume>
               <fpage>2395</fpage>
               <lpage>2404</lpage>
            </element-citation>
         </ref>
         <ref id="ref70">
            <element-citation publication-type="journal" id="cit70">
               <name name-style="western">
                  <surname>Ciceri</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Müller</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>O’Mahony</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fedorov</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Filippakopoulos</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hunt</surname>
                  <given-names>J. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lasater</surname>
                  <given-names>E. a</given-names>
               </name>
               <name name-style="western">
                  <surname>Pallares</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Picaud</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wells</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Martin</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wodicka</surname>
                  <given-names>L. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shah</surname>
                  <given-names>N. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Treiber</surname>
                  <given-names>D. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Knapp</surname>
                  <given-names>S.</given-names>
               </name>
               <article-title>Dual kinase-bromodomain inhibitors
for rationally designed polypharmacology</article-title>
               <source>Nat.
Chem. Biol.</source>
               <year>2014</year>
               <volume>10</volume>
               <fpage>305</fpage>
               <lpage>312</lpage>
            </element-citation>
         </ref>
         <ref id="ref71">
            <element-citation publication-type="journal" id="cit71">
               <name name-style="western">
                  <surname>Ember</surname>
                  <given-names>S. W.
J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhu</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Olesen</surname>
                  <given-names>S. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Martin</surname>
                  <given-names>M. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Becker</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Berndt</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Georg</surname>
                  <given-names>G. I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Scho</surname>
                  <given-names>E.</given-names>
               </name>
               <article-title>Acetyl-lysine binding
site of bromodomain-containing protein 4 (BRD4) interacts with diverse
kinase inhibitors</article-title>
               <source>ACS Chem. Biol.</source>
               <year>2014</year>
               <volume>9</volume>
               <fpage>1160</fpage>
               <lpage>1171</lpage>
            </element-citation>
         </ref>
         <ref id="ref72">
            <element-citation publication-type="journal" id="cit72">
               <name name-style="western">
                  <surname>Baud</surname>
                  <given-names>M. G. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lin-Shiao</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cardote</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tallant</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pschibul</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chan</surname>
                  <given-names>K.-H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zengerle</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Garcia</surname>
                  <given-names>J. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kwan</surname>
                  <given-names>T. T.-L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ferguson</surname>
                  <given-names>F. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ciulli</surname>
                  <given-names>A.</given-names>
               </name>
               <article-title>A bump-and-hole approach to engineer
controlled selectivity of BET bromodomain chemical probes</article-title>
               <source>Science</source>
               <year>2014</year>
               <volume>346</volume>
               <fpage>638</fpage>
               <lpage>641</lpage>
            </element-citation>
         </ref>
         <ref id="ref73">
            <element-citation publication-type="journal" id="cit73">
               <name name-style="western">
                  <surname>Bishop</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Buzko</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jung</surname>
                  <given-names>I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kraybill</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Liu</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shah</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ulrich</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Witucki</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shokat</surname>
                  <given-names>K. M.</given-names>
               </name>
               <article-title>Unnatural ligands for engineered
proteins: new tools for chemical genetics</article-title>
               <source>Annu.
Rev. Biophys. Biomol. Struct.</source>
               <year>2000</year>
               <volume>29</volume>
               <fpage>577</fpage>
               <lpage>606</lpage>
            </element-citation>
         </ref>
         <ref id="ref74">
            <mixed-citation publication-type="patent" id="cit74"><person-group person-group-type="allauthors"><name name-style="western"><surname>Amans</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Bamborough</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Bit</surname><given-names>R.
A.</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>J.
A.</given-names></name>, <name name-style="western"><surname>Campbell</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Lindon</surname><given-names>M. J.</given-names></name>, <name name-style="western"><surname>Shipley</surname><given-names>T. J.</given-names></name>, <name name-style="western"><surname>Theodoulou</surname><given-names>N. H.</given-names></name>, <name name-style="western"><surname>Wellaway</surname><given-names>C. R.</given-names></name>, and <name name-style="western"><surname>Westaway</surname><given-names>S. M.</given-names></name></person-group> (<year>2014</year>) <article-title>Thieno­[3,2-c]­pyridin-4­(5h)-ones as BET inhibitors</article-title>. <patent>WO2014078257</patent>.</mixed-citation>
         </ref>
         <ref id="ref75">
            <mixed-citation publication-type="patent" id="cit75"><person-group person-group-type="allauthors"><name name-style="western"><surname>Amans</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Atkinson</surname><given-names>S. J.</given-names></name>, <name name-style="western"><surname>Harrison</surname><given-names>L. A.</given-names></name>, <name name-style="western"><surname>Hirst</surname><given-names>D. J.</given-names></name>, <name name-style="western"><surname>Law</surname><given-names>R. P.</given-names></name>, <name name-style="western"><surname>Lindon</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Preston</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Seal</surname><given-names>J.
T.</given-names></name>, and <name name-style="western"><surname>Wellaway</surname><given-names>C. R.</given-names></name></person-group> (<year>2014</year>) <article-title>2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives
and their use as bromodomain inhibitors</article-title>. <patent>WO2014140076</patent>.</mixed-citation>
         </ref>
         <ref id="ref76">
            <mixed-citation publication-type="patent" id="cit76"><person-group person-group-type="allauthors"><name name-style="western"><surname>Amans</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Bamborough</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Barker</surname><given-names>M. D.</given-names></name>, <name name-style="western"><surname>Bit</surname><given-names>R. A.</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>J. A.</given-names></name>, <name name-style="western"><surname>Campbell</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Garton</surname><given-names>N. S.</given-names></name>, <name name-style="western"><surname>Lindon</surname><given-names>M. J.</given-names></name>, <name name-style="western"><surname>Shipley</surname><given-names>T. J.</given-names></name>, <name name-style="western"><surname>Theodoulou</surname><given-names>N. H.</given-names></name>, <name name-style="western"><surname>Wellaway</surname><given-names>C. R.</given-names></name>, and <name name-style="western"><surname>Westaway</surname><given-names>S. M.</given-names></name></person-group> (<year>2014</year>) <article-title>Furopyridines as bromodomain inhibitors</article-title>. <patent>WO2014140077</patent>.</mixed-citation>
         </ref>
         <ref id="ref77">
            <mixed-citation publication-type="patent" id="cit77"><person-group person-group-type="allauthors"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Pratt</surname><given-names>J.
K.</given-names></name>, <name name-style="western"><surname>McDaniel</surname><given-names>K. F.</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Fidanze</surname><given-names>S. D.</given-names></name>, <name name-style="western"><surname>Hasvold</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Holms</surname><given-names>J.
H.</given-names></name>, <name name-style="western"><surname>Kati</surname><given-names>W.
M.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Mantei</surname><given-names>R. A.</given-names></name>, <name name-style="western"><surname>McClellan</surname><given-names>W. J.</given-names></name>, <name name-style="western"><surname>Sheppard</surname><given-names>G. S.</given-names></name>, and <name name-style="western"><surname>Wada</surname><given-names>C. K.</given-names></name></person-group> (<year>2014</year>) <article-title>Bromodomain
inhibitors</article-title>. <patent>US20140162971</patent>.</mixed-citation>
         </ref>
         <ref id="ref78">
            <element-citation publication-type="journal" id="cit78">
               <name name-style="western">
                  <surname>Crawford</surname>
                  <given-names>N. P. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Alsarraj</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lukes</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Walker</surname>
                  <given-names>R. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Officewala</surname>
                  <given-names>J. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>H. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>M. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ozato</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hunter</surname>
                  <given-names>K. W.</given-names>
               </name>
               <article-title>Bromodomain
4 activation predicts breast cancer survival</article-title>
               <source>Proc. Natl. Acad. Sci. U.S.A.</source>
               <year>2008</year>
               <volume>105</volume>
               <fpage>6380</fpage>
               <lpage>6385</lpage>
            </element-citation>
         </ref>
         <ref id="ref79">
            <element-citation publication-type="journal" id="cit79">
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tang</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cole</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Marmorstein</surname>
                  <given-names>R.</given-names>
               </name>
               <article-title>Structure
and chemistry of the p300/CBP and Rtt109 histone acetyltransferases:
implications for histone acetyltransferase evolution and function</article-title>
               <source>Curr. Opin. Struct. Biol.</source>
               <year>2008</year>
               <volume>18</volume>
               <fpage>741</fpage>
               <lpage>747</lpage>
            </element-citation>
         </ref>
         <ref id="ref80">
            <element-citation publication-type="journal" id="cit80">
               <name name-style="western">
                  <surname>Bannister</surname>
                  <given-names>A. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kouzarides</surname>
                  <given-names>T.</given-names>
               </name>
               <article-title>The CBP co-activator is a histone acetyltransferase</article-title>
               <source>Nature</source>
               <year>1996</year>
               <volume>384</volume>
               <fpage>641</fpage>
               <lpage>643</lpage>
            </element-citation>
         </ref>
         <ref id="ref81">
            <element-citation publication-type="journal" id="cit81">
               <name name-style="western">
                  <surname>Ogryzko</surname>
                  <given-names>V. V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schiltz</surname>
                  <given-names>R. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Russanova</surname>
                  <given-names>V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Howard</surname>
                  <given-names>B. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nakatani</surname>
                  <given-names>Y.</given-names>
               </name>
               <article-title>The transcriptional
coactivators p300 and CBP are histone acetyltransferases</article-title>
               <source>Cell</source>
               <year>1996</year>
               <volume>87</volume>
               <fpage>953</fpage>
               <lpage>959</lpage>
            </element-citation>
         </ref>
         <ref id="ref82">
            <element-citation publication-type="journal" id="cit82">
               <name name-style="western">
                  <surname>Bedford</surname>
                  <given-names>D.
C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kasper</surname>
                  <given-names>L. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fukuyama</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brindle</surname>
                  <given-names>P. K.</given-names>
               </name>
               <article-title>Target gene context
influences the transcriptional requirement for the KAT3 family of
CBP and p300 histone acetyltransferases</article-title>
               <source>Epigenetics</source>
               <year>2010</year>
               <volume>5</volume>
               <fpage>9</fpage>
               <lpage>15</lpage>
            </element-citation>
         </ref>
         <ref id="ref83">
            <element-citation publication-type="journal" id="cit83">
               <name name-style="western">
                  <surname>Sachchidanand</surname>
               </name>
               <name name-style="western">
                  <surname>Resnick-Silverman</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yan</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mutjaba</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Liu</surname>
                  <given-names>W.-J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zeng</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Manfredi</surname>
                  <given-names>J. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhou</surname>
                  <given-names>M.-M.</given-names>
               </name>
               <article-title>Target
structure-based discovery of small molecules
that block human p53 and CREB binding protein association</article-title>
               <source>Chem. Biol.</source>
               <year>2006</year>
               <volume>13</volume>
               <fpage>81</fpage>
               <lpage>90</lpage>
            </element-citation>
         </ref>
         <ref id="ref84">
            <element-citation publication-type="journal" id="cit84">
               <name name-style="western">
                  <surname>Gerona-navarro</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rodríguez-fernández</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mujtaba</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Patel</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zeng</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Plotnikov</surname>
                  <given-names>A. N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Osman</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhou</surname>
                  <given-names>M.</given-names>
               </name>
               <article-title>Rational design
of cyclic peptide modulators of the transcriptional co-activator CBP:
a new class of p53 inhibitors</article-title>
               <source>J. Am. Chem.
Soc.</source>
               <year>2011</year>
               <volume>133</volume>
               <fpage>2040</fpage>
               <lpage>2043</lpage>
            </element-citation>
         </ref>
         <ref id="ref85">
            <element-citation publication-type="journal" id="cit85">
               <name name-style="western">
                  <surname>Rooney</surname>
                  <given-names>T.
P. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Filippakopoulos</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fedorov</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Picaud</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cortopassi</surname>
                  <given-names>W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hay</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Martin</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tumber</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rogers</surname>
                  <given-names>C. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Philpott</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Thompson</surname>
                  <given-names>A. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Heightman</surname>
                  <given-names>T. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pryde</surname>
                  <given-names>D. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cook</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Paton</surname>
                  <given-names>R. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Müller</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Knapp</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brennan</surname>
                  <given-names>P. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Conway</surname>
                  <given-names>S. J.</given-names>
               </name>
               <article-title>A series
of potent CREBBP bromodomain ligands reveals an induced-fit pocket
stabilized by a cation-π interaction</article-title>
               <source>Angew. Chem., Int. Ed.</source>
               <year>2014</year>
               <volume>53</volume>
               <fpage>6126</fpage>
               <lpage>6130</lpage>
            </element-citation>
         </ref>
         <ref id="ref86">
            <mixed-citation publication-type="weblink" id="cit86"><collab>SGC</collab> (<year>2014</year>). <article-title>I-CBP112: a CREBBP/EP300-selective
chemical probe</article-title>. <uri>http://www.thesgc.org/chemical-probes/ICBP112</uri> (accessed November 19, 2014).</mixed-citation>
         </ref>
         <ref id="ref87">
            <element-citation publication-type="journal" id="cit87">
               <name name-style="western">
                  <surname>Fedorov</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lingard</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wells</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Monteiro</surname>
                  <given-names>O. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Picaud</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Keates</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yapp</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Philpott</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Martin</surname>
                  <given-names>S. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Felletar</surname>
                  <given-names>I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Marsden</surname>
                  <given-names>B. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Filippakopoulos</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mu</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Knapp</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brennan</surname>
                  <given-names>P. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Drive</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ox</surname>
                  <given-names>O.</given-names>
               </name>
               <article-title>[1,2,4]­Triazolo­[4,3-a]­phthalzines:
inhibitors of diverse bromodomains</article-title>
               <source>J. Med.
Chem.</source>
               <year>2014</year>
               <volume>57</volume>
               <fpage>462</fpage>
               <lpage>476</lpage>
            </element-citation>
         </ref>
         <ref id="ref88">
            <mixed-citation publication-type="patent" id="cit88"><person-group person-group-type="allauthors"><name name-style="western"><surname>Chung</surname><given-names>C.-W.</given-names></name>, and <name name-style="western"><surname>Nicodeme</surname><given-names>E.</given-names></name></person-group> (<year>2011</year>) <article-title>Quinoline, azoloquinoline, triazolobenzodiazepine derivatives as
bromodomain inhibitors for treating autoimmune and inflammatory diseases
and their preparation</article-title>. <patent>WO2011054843A1</patent>.</mixed-citation>
         </ref>
         <ref id="ref89">
            <mixed-citation publication-type="patent" id="cit89"><person-group person-group-type="allauthors"><name name-style="western"><surname>Albrecht</surname><given-names>B. K.</given-names></name>, <name name-style="western"><surname>Harmange</surname><given-names>J.-C.</given-names></name>, <name name-style="western"><surname>Cote</surname><given-names>A.</given-names></name>, and <name name-style="western"><surname>Taylor</surname><given-names>A. M.</given-names></name></person-group> (<year>2012</year>) <article-title>Bromodomain inhibitors and uses thereof</article-title>. <patent>US20140296243</patent>.</mixed-citation>
         </ref>
         <ref id="ref90">
            <element-citation publication-type="journal" id="cit90">
               <name name-style="western">
                  <surname>Ruegg</surname>
                  <given-names>U. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Burgess</surname>
                  <given-names>G. M.</given-names>
               </name>
               <article-title>Staurosporine, K-252
and UCN-01: potent but nonspecific
inhibitors of protein kmases</article-title>
               <source>Trends Pharmacol.
Sci.</source>
               <year>1989</year>
               <volume>10</volume>
               <fpage>218</fpage>
               <lpage>220</lpage>
            </element-citation>
         </ref>
         <ref id="ref91">
            <mixed-citation publication-type="weblink" id="cit91"><collab>SGC</collab> (<year>2014</year>). <article-title>Bromosporine</article-title>. <uri>http://www.thesgc.org/chemical-probes/bromosporine</uri> (accessed
November 19, 2014).</mixed-citation>
         </ref>
         <ref id="ref92">
            <element-citation publication-type="journal" id="cit92">
               <name name-style="western">
                  <surname>Ferguson</surname>
                  <given-names>F.
M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fedorov</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chaikuad</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Philpott</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Muniz</surname>
                  <given-names>J. R. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Felletar</surname>
                  <given-names>I.</given-names>
               </name>
               <name name-style="western">
                  <surname>von Delft</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Heightman</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Knapp</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Abell</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ciulli</surname>
                  <given-names>A.</given-names>
               </name>
               <article-title>Targeting low-druggability
bromodomains: fragment based screening and inhibitor design against
the BAZ2B bromodomain</article-title>
               <source>J. Med. Chem.</source>
               <year>2013</year>
               <volume>56</volume>
               <fpage>10183</fpage>
               <lpage>10187</lpage>
            </element-citation>
         </ref>
         <ref id="ref93">
            <mixed-citation publication-type="weblink" id="cit93"><collab>SGC</collab> (<year>2014</year>). <article-title>GSK2801: A selective
chemical probe for BAZ2B/A bromodomains</article-title>. <uri>http://www.thesgc.org/chemical-probes/GSK2801</uri> (accessed November 19, 2014).</mixed-citation>
         </ref>
         <ref id="ref94">
            <mixed-citation publication-type="weblink" id="cit94"><collab>SGC</collab> (<year>2014</year>). <article-title>PFI-3: Selective
chemical probe for SMARCA bromodomains</article-title>. <uri>http://www.thesgc.org/chemical-probes/PFI-3</uri> (accessed November 19, 2014).</mixed-citation>
         </ref>
         <ref id="ref95">
            <element-citation publication-type="journal" id="cit95">
               <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sanchez</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhou</surname>
                  <given-names>M.-M.</given-names>
               </name>
               <article-title>Scaling the druggability landscape
of human bromodomains, a new class of drug targets</article-title>
               <source>J. Med. Chem.</source>
               <year>2012</year>
               <volume>55</volume>
               <fpage>7342</fpage>
               <lpage>7345</lpage>
            </element-citation>
         </ref>
         <ref id="ref96">
            <element-citation publication-type="journal" id="cit96">
               <name name-style="western">
                  <surname>Hopkinson</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Walport</surname>
                  <given-names>L. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Münzel</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rose</surname>
                  <given-names>N. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Smart</surname>
                  <given-names>T. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kawamura</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Claridge</surname>
                  <given-names>T. D. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schofield</surname>
                  <given-names>C. J.</given-names>
               </name>
               <article-title>Is JmjC
oxygenase catalysis limited to demethylation?</article-title>
               <source>Angew. Chem., Int. Ed.</source>
               <year>2013</year>
               <volume>52</volume>
               <fpage>7709</fpage>
               <lpage>7713</lpage>
            </element-citation>
         </ref>
         <ref id="ref97">
            <element-citation publication-type="journal" id="cit97">
               <name name-style="western">
                  <surname>Poplawski</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hu</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Natesan</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Peng</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Carlson</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shi</surname>
                  <given-names>X.</given-names>
               </name>
               <name name-style="western">
                  <surname>Balaz</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Markley</surname>
                  <given-names>J. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Glass</surname>
                  <given-names>K. C.</given-names>
               </name>
               <article-title>Molecular insights
into the recognition of N-terminal histone modifications by the BRPF1
bromodomain</article-title>
               <source>J. Mol. Biol.</source>
               <year>2014</year>
               <volume>426</volume>
               <fpage>1661</fpage>
               <lpage>1676</lpage>
            </element-citation>
         </ref>
         <ref id="ref98">
            <element-citation publication-type="journal" id="cit98">
               <name name-style="western">
                  <surname>Muvva</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Singam</surname>
                  <given-names>E. R. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Raman</surname>
                  <given-names>S. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Subramanian</surname>
                  <given-names>V.</given-names>
               </name>
               <article-title>Structure-based
virtual screening of novel, high-affinity BRD4 inhibitors</article-title>
               <source>Mol. Biosyst.</source>
               <year>2014</year>
               <volume>10</volume>
               <fpage>2384</fpage>
               <lpage>2397</lpage>
            </element-citation>
         </ref>
         <ref id="ref99">
            <element-citation publication-type="journal" id="cit99">
               <name name-style="western">
                  <surname>Liu</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>X.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Huang</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ding</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wu</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shi</surname>
                  <given-names>Y.</given-names>
               </name>
               <article-title>Structural basis and binding properties of the second
bromodomain of Brd4 with acetylated histone tails</article-title>
               <source>Biochemistry</source>
               <year>2008</year>
               <volume>12</volume>
               <fpage>6403</fpage>
               <lpage>6417</lpage>
            </element-citation>
         </ref>
         <ref id="ref100">
            <element-citation publication-type="journal" id="cit100">
               <name name-style="western">
                  <surname>Zhao</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gartenmann</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dong</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Spiliotopoulos</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Caflisch</surname>
                  <given-names>A.</given-names>
               </name>
               <article-title>Discovery of BRD4 bromodomain inhibitors by fragment-based
high-throughput docking</article-title>
               <source>Bioorg. Med. Chem.
Lett.</source>
               <year>2014</year>
               <volume>24</volume>
               <fpage>2493</fpage>
               <lpage>2496</lpage>
            </element-citation>
         </ref>
         <ref id="ref101">
            <element-citation publication-type="journal" id="cit101">
               <name name-style="western">
                  <surname>Pantano</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Marcello</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ferrari</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gaudiosi</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sabò</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pellegrini</surname>
                  <given-names>V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Beltram</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Giacca</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Carloni</surname>
                  <given-names>P.</given-names>
               </name>
               <article-title>Insights on HIV-1 Tat:P/CAF
bromodomain molecular recognition
from in vivo experiments and molecular dynamics simulations</article-title>
               <source>Proteins</source>
               <year>2006</year>
               <volume>62</volume>
               <fpage>1062</fpage>
               <lpage>1073</lpage>
            </element-citation>
         </ref>
         <ref id="ref102">
            <element-citation publication-type="journal" id="cit102">
               <name name-style="western">
                  <surname>Eldridge</surname>
                  <given-names>M. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Murray</surname>
                  <given-names>C. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Auton</surname>
                  <given-names>T. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Paolini</surname>
                  <given-names>G. V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mee</surname>
                  <given-names>R. P.</given-names>
               </name>
               <article-title>Empirical
scoring functions: I. The development of
a fast empirical scoring function to estimate the binding affinity
of ligands in receptor complexes</article-title>
               <source>J. Comput.-Aided.
Mol. Des.</source>
               <year>1997</year>
               <volume>11</volume>
               <fpage>425</fpage>
               <lpage>445</lpage>
            </element-citation>
         </ref>
         <ref id="ref103">
            <element-citation publication-type="journal" id="cit103">
               <name name-style="western">
                  <surname>Morris</surname>
                  <given-names>G.
M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Goodsell</surname>
                  <given-names>D. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Halliday</surname>
                  <given-names>R. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Huey</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hart</surname>
                  <given-names>W. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Belew</surname>
                  <given-names>R. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Olson</surname>
                  <given-names>A. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Al</surname>
                  <given-names>M. E. T.</given-names>
               </name>
               <article-title>Automated
docking using a lamarckian genetic algorithm and an empirical binding
free energy function</article-title>
               <source>J. Comput. Chem.</source>
               <year>1998</year>
               <volume>19</volume>
               <fpage>1639</fpage>
               <lpage>1662</lpage>
            </element-citation>
         </ref>
         <ref id="ref104">
            <element-citation publication-type="journal" id="cit104">
               <name name-style="western">
                  <surname>Huang</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rossini</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Steiner</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Caflisch</surname>
                  <given-names>A.</given-names>
               </name>
               <article-title>Structured
water molecules in the binding site of bromodomains can be displaced
by cosolvent</article-title>
               <source>ChemMedChem</source>
               <year>2014</year>
               <volume>9</volume>
               <fpage>573</fpage>
               <lpage>579</lpage>
            </element-citation>
         </ref>
         <ref id="ref105">
            <element-citation publication-type="journal" id="cit105">
               <name name-style="western">
                  <surname>MacKerell</surname>
                  <given-names>a D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bashford</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bellott</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dunbrack</surname>
                  <given-names>R. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Evanseck</surname>
                  <given-names>J. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Field</surname>
                  <given-names>M. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fischer</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gao</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Guo</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ha</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Joseph-McCarthy</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kuchnir</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kuczera</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lau</surname>
                  <given-names>F. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mattos</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Michnick</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ngo</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nguyen</surname>
                  <given-names>D. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Prodhom</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Reiher</surname>
                  <given-names>W. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Roux</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schlenkrich</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Smith</surname>
                  <given-names>J. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Stote</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Straub</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Watanabe</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wiórkiewicz-Kuczera</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yin</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Karplus</surname>
                  <given-names>M.</given-names>
               </name>
               <article-title>All-atom empirical potential for molecular modeling
and dynamics studies of proteins</article-title>
               <source>J. Phys. Chem.
B</source>
               <year>1998</year>
               <volume>102</volume>
               <fpage>3586</fpage>
               <lpage>3616</lpage>
            </element-citation>
         </ref>
         <ref id="ref106">
            <element-citation publication-type="journal" id="cit106">
               <name name-style="western">
                  <surname>Vidler</surname>
                  <given-names>L.
R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Filippakopoulos</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fedorov</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Picaud</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Martin</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tomsett</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Woodward</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brown</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Knapp</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hoelder</surname>
                  <given-names>S.</given-names>
               </name>
               <article-title>Discovery
of novel small-molecule
inhibitors of BRD4 using structure-based virtual screening</article-title>
               <source>J. Med. Chem.</source>
               <year>2013</year>
               <volume>56</volume>
               <fpage>8073</fpage>
               <lpage>8088</lpage>
            </element-citation>
         </ref>
         <ref id="ref107">
            <element-citation publication-type="journal" id="cit107">
               <name name-style="western">
                  <surname>Trellet</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Melquiond</surname>
                  <given-names>A. S. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bonvin</surname>
                  <given-names>A. M. J. J.</given-names>
               </name>
               <article-title>A unified
conformational selection and induced fit approach to protein-peptide
docking</article-title>
               <source>PLoS One</source>
               <year>2013</year>
               <volume>8</volume>
               <fpage>e58769</fpage>
            </element-citation>
         </ref>
         <ref id="ref108">
            <element-citation publication-type="journal" id="cit108">
               <name name-style="western">
                  <surname>Ferguson</surname>
                  <given-names>F. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dias</surname>
                  <given-names>D. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rodrigues</surname>
                  <given-names>P. G. L. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wienk</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Boelens</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bonvin</surname>
                  <given-names>A. M. J. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Abell</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ciulli</surname>
                  <given-names>A.</given-names>
               </name>
               <article-title>Binding hotspots of
BAZ2B bromodomain:
Histone interaction revealed by solution NMR driven docking</article-title>
               <source>Biochemistry</source>
               <year>2014</year>
               <volume>53</volume>
               <fpage>6706</fpage>
               <lpage>6716</lpage>
            </element-citation>
         </ref>
         <ref id="ref109">
            <element-citation publication-type="journal" id="cit109">
               <name name-style="western">
                  <surname>Vidler</surname>
                  <given-names>L. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brown</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Knapp</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hoelder</surname>
                  <given-names>S.</given-names>
               </name>
               <article-title>Druggability
analysis and structural classification of bromodomain acetyl-lysine
binding sites</article-title>
               <source>J. Med. Chem.</source>
               <year>2012</year>
               <volume>55</volume>
               <fpage>7346</fpage>
               <lpage>7359</lpage>
            </element-citation>
         </ref>
         <ref id="ref110">
            <element-citation publication-type="journal" id="cit110">
               <name name-style="western">
                  <surname>Halgren</surname>
                  <given-names>T.</given-names>
               </name>
               <article-title>Identifying and characterizing binding sites and assessing
druggability</article-title>
               <source>J. Chem. Inf. Model.</source>
               <year>2009</year>
               <volume>49</volume>
               <fpage>377</fpage>
               <lpage>389</lpage>
            </element-citation>
         </ref>
         <ref id="ref111">
            <element-citation publication-type="journal" id="cit111">
               <name name-style="western">
                  <surname>Halgren</surname>
                  <given-names>T.</given-names>
               </name>
               <article-title>New method for fast and accurate
binding-site identification
and analysis</article-title>
               <source>Chem. Biol. Drug Des.</source>
               <year>2007</year>
               <volume>69</volume>
               <fpage>146</fpage>
               <lpage>148</lpage>
            </element-citation>
         </ref>
         <ref id="ref112">
            <element-citation publication-type="journal" id="cit112">
               <name name-style="western">
                  <surname>Steiner</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Magno</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Huang</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Caflisch</surname>
                  <given-names>A.</given-names>
               </name>
               <article-title>Does bromodomain
flexibility influence histone recognition?</article-title>
               <source>FEBS Lett.</source>
               <year>2013</year>
               <volume>587</volume>
               <fpage>2158</fpage>
               <lpage>2163</lpage>
            </element-citation>
         </ref>
         <ref id="ref113">
            <element-citation publication-type="journal" id="cit113">
               <name name-style="western">
                  <surname>Mirguet</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lamotte</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chung</surname>
                  <given-names>C.-W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bamborough</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Delannée</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bouillot</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gellibert</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Krysa</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lewis</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Witherington</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Huet</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dudit</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Trottet</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nicodeme</surname>
                  <given-names>E.</given-names>
               </name>
               <article-title>Naphthyridines
as novel BET family bromodomain inhibitors</article-title>
               <source>ChemMedChem</source>
               <year>2014</year>
               <volume>9</volume>
               <fpage>580</fpage>
               <lpage>589</lpage>
            </element-citation>
         </ref>
         <ref id="ref114">
            <element-citation publication-type="journal" id="cit114">
               <name name-style="western">
                  <surname>Meslamani</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Smith</surname>
                  <given-names>S. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sanchez</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhou</surname>
                  <given-names>M.-M.</given-names>
               </name>
               <article-title>ChEpiMod:
a knowledgebase for chemical modulators of epigenome reader domains</article-title>
               <source>Bioinformatics</source>
               <year>2014</year>
               <volume>30</volume>
               <fpage>1481</fpage>
               <lpage>1483</lpage>
            </element-citation>
         </ref>
         <ref id="ref115">
            <element-citation publication-type="journal" id="cit115">
               <name name-style="western">
                  <surname>Gallivan</surname>
                  <given-names>J. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dougherty</surname>
                  <given-names>D.</given-names>
               </name>
               <article-title>Cation-pi interactions in structural
biology</article-title>
               <source>Proc. Natl. Acad. Sci. U.S.A.</source>
               <year>1999</year>
               <volume>96</volume>
               <fpage>9459</fpage>
               <lpage>9464</lpage>
            </element-citation>
         </ref>
         <ref id="ref116">
            <element-citation publication-type="journal" id="cit116">
               <name name-style="western">
                  <surname>Stigliani</surname>
                  <given-names>J.-L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bernardes-Génisson</surname>
                  <given-names>V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bernadou</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pratviel</surname>
                  <given-names>G.</given-names>
               </name>
               <article-title>Cross-docking study on InhA inhibitors:
a combination
of Autodock Vina and PM6-DH2 simulations to retrieve bio-active conformations</article-title>
               <source>Org. Biomol. Chem.</source>
               <year>2012</year>
               <volume>10</volume>
               <fpage>6341</fpage>
               <lpage>6349</lpage>
            </element-citation>
         </ref>
         <ref id="ref117">
            <element-citation publication-type="journal" id="cit117">
               <name name-style="western">
                  <surname>Chaires</surname>
                  <given-names>J. B.</given-names>
               </name>
               <article-title>Calorimetry
and thermodynamics in drug design</article-title>
               <source>Annu. Rev.
Biophys.</source>
               <year>2008</year>
               <volume>37</volume>
               <fpage>135</fpage>
               <lpage>151</lpage>
            </element-citation>
         </ref>
         <ref id="ref118">
            <element-citation publication-type="journal" id="cit118">
               <name name-style="western">
                  <surname>Lea</surname>
                  <given-names>W. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Simeonov</surname>
                  <given-names>A.</given-names>
               </name>
               <article-title>Fluorescence polarization
assays
in small molecule screening</article-title>
               <source>Expert Opin. Drug
Discovery</source>
               <year>2011</year>
               <volume>6</volume>
               <fpage>17</fpage>
               <lpage>32</lpage>
            </element-citation>
         </ref>
         <ref id="ref119">
            <element-citation publication-type="journal" id="cit119">
               <name name-style="western">
                  <surname>Silvestre</surname>
                  <given-names>H. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Blundell</surname>
                  <given-names>T. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Abell</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ciulli</surname>
                  <given-names>A.</given-names>
               </name>
               <article-title>Integrated
biophysical approach to fragment screening and validation for fragment-based
lead discovery</article-title>
               <source>Proc. Natl. Acad. Sci. U.S.A.</source>
               <year>2013</year>
               <volume>110</volume>
               <fpage>12984</fpage>
               <lpage>12989</lpage>
            </element-citation>
         </ref>
         <ref id="ref120">
            <element-citation publication-type="journal" id="cit120">
               <name name-style="western">
                  <surname>Chung</surname>
                  <given-names>C.-W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Witherington</surname>
                  <given-names>J.</given-names>
               </name>
               <article-title>Progress in
the discovery of small-molecule
inhibitors of bromodomain--histone interactions</article-title>
               <source>J. Biomol. Screening</source>
               <year>2011</year>
               <volume>16</volume>
               <fpage>1170</fpage>
               <lpage>1185</lpage>
            </element-citation>
         </ref>
         <ref id="ref121">
            <element-citation publication-type="journal" id="cit121">
               <name name-style="western">
                  <surname>Hassan</surname>
                  <given-names>A. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Awad</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Al-Natour</surname>
                  <given-names>Z.</given-names>
               </name>
               <name name-style="western">
                  <surname>Othman</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mustafa</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rizvi</surname>
                  <given-names>T.</given-names>
               </name>
               <article-title>Selective recognition
of acetylated histones by bromodomains in transcriptional co-activators</article-title>
               <source>Biochem. J.</source>
               <year>2007</year>
               <volume>402</volume>
               <fpage>125</fpage>
               <lpage>133</lpage>
            </element-citation>
         </ref>
         <ref id="ref122">
            <element-citation publication-type="journal" id="cit122">
               <name name-style="western">
                  <surname>Hu</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>X.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>Q.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>Z.</given-names>
               </name>
               <article-title>Fluorescence
polarization for the evaluation of small-molecule inhibitors
of PCAF BRD/Tat-AcK50 association</article-title>
               <source>ChemMedChem</source>
               <year>2014</year>
               <volume>9</volume>
               <fpage>928</fpage>
               <lpage>931</lpage>
            </element-citation>
         </ref>
         <ref id="ref123">
            <element-citation publication-type="journal" id="cit123">
               <name name-style="western">
                  <surname>Falconer</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Penkova</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jelesarov</surname>
                  <given-names>I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Collins</surname>
                  <given-names>B. M.</given-names>
               </name>
               <article-title>Survey of the year 2008: applications of isothermal
titration calorimetry</article-title>
               <source>J. Mol. Recognit.</source>
               <year>2010</year>
               <volume>23</volume>
               <fpage>395</fpage>
               <lpage>413</lpage>
            </element-citation>
         </ref>
         <ref id="ref124">
            <element-citation publication-type="journal" id="cit124">
               <name name-style="western">
                  <surname>Tsai</surname>
                  <given-names>W.-W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>Z.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yiu</surname>
                  <given-names>T. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Akdemir</surname>
                  <given-names>K. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Xia</surname>
                  <given-names>W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Winter</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tsai</surname>
                  <given-names>C.-Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shi</surname>
                  <given-names>X.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schwarzer</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Plunkett</surname>
                  <given-names>W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Aronow</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gozani</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fischle</surname>
                  <given-names>W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hung</surname>
                  <given-names>M.-C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Patel</surname>
                  <given-names>D. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Barton</surname>
                  <given-names>M. C.</given-names>
               </name>
               <article-title>TRIM24
links a non-canonical
histone signature to breast cancer</article-title>
               <source>Nature</source>
               <year>2010</year>
               <volume>468</volume>
               <fpage>927</fpage>
               <lpage>932</lpage>
            </element-citation>
         </ref>
         <ref id="ref125">
            <element-citation publication-type="journal" id="cit125">
               <name name-style="western">
                  <surname>Zeng</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Li</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Muller</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yan</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mujtaba</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pan</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>Z.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhou</surname>
                  <given-names>M.-M.</given-names>
               </name>
               <article-title>Selective
small molecules blocking HIV-1 Tat and coactivator PCAF association</article-title>
               <source>J. Am. Chem. Soc.</source>
               <year>2005</year>
               <volume>127</volume>
               <fpage>2376</fpage>
               <lpage>2377</lpage>
            </element-citation>
         </ref>
         <ref id="ref126">
            <element-citation publication-type="journal" id="cit126">
               <name name-style="western">
                  <surname>Kanno</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kanno</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Siegel</surname>
                  <given-names>R. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jang</surname>
                  <given-names>M. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lenardo</surname>
                  <given-names>M. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ozato</surname>
                  <given-names>K.</given-names>
               </name>
               <article-title>Selective recognition of acetylated
histones by bromodomain proteins visualized in living cells</article-title>
               <source>Mol. Cell</source>
               <year>2004</year>
               <volume>13</volume>
               <fpage>33</fpage>
               <lpage>43</lpage>
            </element-citation>
         </ref>
         <ref id="ref127">
            <element-citation publication-type="journal" id="cit127">
               <name name-style="western">
                  <surname>Philpott</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rogers</surname>
                  <given-names>C. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yapp</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wells</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lambert</surname>
                  <given-names>J.-P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Strain-Damerell</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Burgess-Brown</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gingras</surname>
                  <given-names>A.-C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Knapp</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Müller</surname>
                  <given-names>S.</given-names>
               </name>
               <article-title>Assessing
cellular efficacy of bromodomain inhibitors using fluorescence recovery
after photobleaching</article-title>
               <source>Epigenetics Chromatin</source>
               <year>2014</year>
               <volume>7</volume>
               <fpage>1</fpage>
               <lpage>12</lpage>
            </element-citation>
         </ref>
         <ref id="ref128">
            <element-citation publication-type="journal" id="cit128">
               <name name-style="western">
                  <surname>Jung</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Philpott</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Müller</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schulze</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Badock</surname>
                  <given-names>V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Eberspächer</surname>
                  <given-names>U.</given-names>
               </name>
               <name name-style="western">
                  <surname>Moosmayer</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bader</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schmees</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fernández-Montalván</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Haendler</surname>
                  <given-names>B.</given-names>
               </name>
               <article-title>Affinity map of bromodomain protein 4 (BRD4) interactions
with the histone H4 tail and the small molecule inhibitor JQ1</article-title>
               <source>J. Biol. Chem.</source>
               <year>2014</year>
               <volume>289</volume>
               <fpage>9304</fpage>
               <lpage>9319</lpage>
            </element-citation>
         </ref>
         <ref id="ref129">
            <element-citation publication-type="journal" id="cit129">
               <name name-style="western">
                  <surname>Wu</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shin</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Williams</surname>
                  <given-names>C. M. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Geoghegan</surname>
                  <given-names>K. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wright</surname>
                  <given-names>S. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Limburg</surname>
                  <given-names>D. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sahasrabudhe</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bonin</surname>
                  <given-names>P. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lefker</surname>
                  <given-names>B. a.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ramsey</surname>
                  <given-names>S. J.</given-names>
               </name>
               <article-title>Design and chemoproteomic
functional characterization of a chemical probe targeted to bromodomains
of BET family proteins</article-title>
               <source>MedChemComm</source>
               <year>2014</year>
               <volume>5</volume>
               <fpage>1871</fpage>
               <lpage>1878</lpage>
            </element-citation>
         </ref>
         <ref id="ref130">
            <element-citation publication-type="journal" id="cit130">
               <name name-style="western">
                  <surname>Demont</surname>
                  <given-names>E. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bamborough</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chung</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Craggs</surname>
                  <given-names>P. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fallon</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gordon</surname>
                  <given-names>L. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Grandi</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hobbs</surname>
                  <given-names>C. I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hussain</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jones</surname>
                  <given-names>E. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gall</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Le Michon</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mitchell</surname>
                  <given-names>D. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Prinjha</surname>
                  <given-names>R. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Roberts</surname>
                  <given-names>A. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sheppard</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Watson</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Road</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sg</surname>
                  <given-names>W.</given-names>
               </name>
               <article-title>1,3-Dimethyl benzimidazolones
are potent, selective inhibitors of the BRPF1 bromodomain</article-title>
               <source>ACS Med. Chem. Lett.</source>
               <year>2014</year>
               <volume>5</volume>
               <fpage>1190</fpage>
               <lpage>1195</lpage>
            </element-citation>
         </ref>
         <ref id="ref131">
            <element-citation publication-type="journal" id="cit131">
               <name name-style="western">
                  <surname>Chapuy</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>McKeown</surname>
                  <given-names>M. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lin</surname>
                  <given-names>C. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Monti</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Roemer</surname>
                  <given-names>M. G. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Qi</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rahl</surname>
                  <given-names>P. B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sun</surname>
                  <given-names>H. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yeda</surname>
                  <given-names>K. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Doench</surname>
                  <given-names>J. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Reichert</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kung</surname>
                  <given-names>A. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rodig</surname>
                  <given-names>S. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Young</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shipp</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bradner</surname>
                  <given-names>J. E.</given-names>
               </name>
               <article-title>Discovery
and characterization of super-enhancer-associated dependencies in
diffuse large B cell lymphoma</article-title>
               <source>Cancer Cell</source>
               <year>2013</year>
               <volume>24</volume>
               <fpage>777</fpage>
               <lpage>790</lpage>
            </element-citation>
         </ref>
         <ref id="ref132">
            <element-citation publication-type="journal" id="cit132">
               <name name-style="western">
                  <surname>Lovén</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hoke</surname>
                  <given-names>H. a</given-names>
               </name>
               <name name-style="western">
                  <surname>Lin</surname>
                  <given-names>C. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lau</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Orlando</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Vakoc</surname>
                  <given-names>C. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bradner</surname>
                  <given-names>J. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>T. I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Young</surname>
                  <given-names>R.</given-names>
               </name>
               <article-title>Selective inhibition of tumor oncogenes by disruption of super-enhancers</article-title>
               <source>Cell</source>
               <year>2013</year>
               <volume>153</volume>
               <fpage>320</fpage>
               <lpage>334</lpage>
            </element-citation>
         </ref>
         <ref id="ref133">
            <element-citation publication-type="journal" id="cit133">
               <name name-style="western">
                  <surname>Hnisz</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Abraham</surname>
                  <given-names>B. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>T. I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lau</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Saint-André</surname>
                  <given-names>V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sigova</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hoke</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Young</surname>
                  <given-names>R.</given-names>
               </name>
               <article-title>Super-enhancers
in the control of cell identity and disease</article-title>
               <source>Cell</source>
               <year>2013</year>
               <volume>155</volume>
               <fpage>934</fpage>
               <lpage>47</lpage>
            </element-citation>
         </ref>
         <ref id="ref134">
            <element-citation publication-type="journal" id="cit134">
               <name name-style="western">
                  <surname>Tang</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gholamin</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schubert</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Willardson</surname>
                  <given-names>M. I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bandopadhayay</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bergthold</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Masoud</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nguyen</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Vue</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Balansay</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yu</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Oh</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Woo</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ponnuswami</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Monje</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Atwood</surname>
                  <given-names>S. X.</given-names>
               </name>
               <name name-style="western">
                  <surname>Whitson</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mitra</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cheshier</surname>
                  <given-names>S. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Qi</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Beroukhim</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tang</surname>
                  <given-names>J. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wechsler-Reya</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Oro</surname>
                  <given-names>A. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Link</surname>
                  <given-names>B. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bradner</surname>
                  <given-names>J. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cho</surname>
                  <given-names>Y.-J.</given-names>
               </name>
               <article-title>Epigenetic
targeting of Hedgehog
pathway transcriptional output through BET bromodomain inhibition</article-title>
               <source>Nat. Med.</source>
               <year>2014</year>
               <fpage>1</fpage>
               <lpage>11</lpage>
            </element-citation>
         </ref>
         <ref id="ref135">
            <element-citation publication-type="journal" id="cit135">
               <name name-style="western">
                  <surname>Asangani</surname>
                  <given-names>I. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dommeti</surname>
                  <given-names>V. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>X.</given-names>
               </name>
               <name name-style="western">
                  <surname>Malik</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cieslik</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Escara-Wilke</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wilder-Romans</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dhanireddy</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Engelke</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Iyer</surname>
                  <given-names>M. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jing</surname>
                  <given-names>X.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wu</surname>
                  <given-names>Y.-M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cao</surname>
                  <given-names>X.</given-names>
               </name>
               <name name-style="western">
                  <surname>Qin</surname>
                  <given-names>Z. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Feng</surname>
                  <given-names>F. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chinnaiyan</surname>
                  <given-names>A. M.</given-names>
               </name>
               <article-title>Therapeutic
targeting of BET bromodomain proteins in castration-resistant prostate
cancer</article-title>
               <source>Nature</source>
               <year>2014</year>
               <volume>510</volume>
               <fpage>278</fpage>
               <lpage>282</lpage>
            </element-citation>
         </ref>
         <ref id="ref136">
            <element-citation publication-type="journal" id="cit136">
               <name name-style="western">
                  <surname>Lamoureux</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Baud’huin</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rodriguez Calleja</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jacques</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Berreur</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rédini</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lecanda</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bradner</surname>
                  <given-names>J. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Heymann</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ory</surname>
                  <given-names>B.</given-names>
               </name>
               <article-title>Selective
inhibition of BET bromodomain epigenetic signalling interferes with
the bone-associated tumour vicious cycle</article-title>
               <source>Nat.
Commun.</source>
               <year>2014</year>
               <volume>5</volume>
               <fpage>3511</fpage>
            </element-citation>
         </ref>
         <ref id="ref137">
            <element-citation publication-type="journal" id="cit137">
               <name name-style="western">
                  <surname>Rajagopalan</surname>
                  <given-names>V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Vaidyanathan</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bradner</surname>
                  <given-names>J. E.</given-names>
               </name>
               <article-title>Pre-clinical analysis
of changes in intra-cellular biochemistry of glioblastoma multiforme
(GBM) cells due to c-Myc silencing</article-title>
               <source>Cell Mol.
Neurobiol</source>
               <year>2014</year>
               <volume>34</volume>
               <fpage>1059</fpage>
               <lpage>1069</lpage>
            </element-citation>
         </ref>
         <ref id="ref138">
            <element-citation publication-type="journal" id="cit138">
               <name name-style="western">
                  <surname>Barrett</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brothers</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wahlestedt</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Beurel</surname>
                  <given-names>E.</given-names>
               </name>
               <article-title>I-BET151 selectively regulates IL-6 production</article-title>
               <source>Biochim. Biophys. Acta</source>
               <year>2014</year>
               <volume>1842</volume>
               <fpage>1549</fpage>
               <lpage>1555</lpage>
            </element-citation>
         </ref>
      </ref-list>
   </back>
</article>
